Novel compounds for inhibiting RET kinase, the manufacturing method thereof and uses therof
A novel RET inhibitory compound, synthesized through a specific reaction, addresses the need for effective inhibitors against RET kinase-driven cancers by exhibiting high inhibitory activity, offering both pharmaceutical and functional food compositions for cancer management.
Patent Information
- Application Number
- KR1020240111945
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2044-08-21
AI Technical Summary
Current treatments for cancers driven by RET kinase mutations, such as non-small cell lung cancer, metastatic colorectal cancer, differentiated thyroid cancer, papillary thyroid carcinoma, and medullary thyroid cancer, lack effective inhibitors with high specificity and efficacy.
Development of a novel RET inhibitory compound represented by Chemical Formula 1 or its pharmaceutically acceptable salts, synthesized through a specific reaction scheme, which exhibits high inhibitory activity against RET kinase and its mutations.
The novel compound effectively inhibits RET kinase and its mutations, providing a pharmaceutical composition for cancer prevention or treatment, as well as a health functional food composition for cancer prevention or improvement.
Smart Images

Figure 112024091161277-PAT00001 
Figure 112024091161277-PAT00002 
Figure 112024091161277-PAT00003
Abstract
Description
Technology Field
[0001] The present invention relates to a novel RET inhibitory compound, a method for preparing the same, and a pharmaceutical composition for the prevention or treatment of cancer containing the same as an active ingredient. Background Technology
[0002] Protein kinases are enzymes that catalyze the phosphorylation of hydroxyl groups located on tyrosine, serine, and threonine residues of proteins, and play an important role in growth factor signaling that induces cell growth, differentiation, and proliferation.
[0003] To maintain homeostasis in the body, the body's signaling pathways must maintain a smooth balance between turning on and off. However, mutations or overexpression of specific protein kinases disrupt normal intracellular signaling pathways (primarily resulting in continued signal transmission), causing various diseases such as cancer, inflammation, metabolic disorders, and brain diseases.
[0004] Receptor tyrosine kinase (RET) is a receptor that can be activated through chromosomal rearrangement, and it is known that abnormalities in the RET gene (point mutations, chromosomal translocations, chromosomal inversions, gene amplification) are involved in carcinogenesis. Abnormal RET activation is the cause of numerous malignancies, including non-small cell lung cancer (NSCLC), metastatic colorectal cancer (mCRC), differentiated thyroid cancer (DTC), papillary thyroid carcinoma (PTC), and medullary thyroid cancer (MTC). The prevalence of RET-positive patients was highest in thyroid cancer (MTC, DTC, PTC) at 36.6%, followed by pancreatic cancer (colorectal cancer) at 17.3%, breast cancer at 6.5%, and lung cancer at over 3%.
[0005] Therefore, compounds having inhibitory activity against RET kinase are very useful for the prevention and treatment of cancer.
[0006] Sorafenib, Sunitinib, Cabozantinib, Vandetanib, and Ponatinib are known to have RET kinase inhibitory activity and inhibit cell proliferation in cell lines expressing KIF5B-RET. Among them, Cabozantinib, a multi-kinase inhibitor, has been reported to have a partial effect in two patients with RET fusion gene-positive non-small cell lung cancer.
[0007] In addition, Korean published patent No. 10-2020-0006495 discloses an N-(3-(imidazo[1,2-b]pyridazine-3-ylethinyl)-4-methylphenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide derivative compound having kinase inhibitory activity.
[0008] Accordingly, efforts were made to develop an anticancer agent that inhibits RET kinase and its mutations, and the present invention was completed by synthesizing a novel compound that exhibits high inhibitory activity against RET kinase and its mutations. The problem to be solved
[0009] One objective of the present invention is to provide a derivative of a novel structure having anticancer activity.
[0010] Another objective of the present invention is to provide a method for manufacturing the novel derivative.
[0011] Another objective of the present invention is to provide a pharmaceutical composition for the prevention or treatment of cancer containing the novel derivative having anticancer activity as an active ingredient. means of solving the problem
[0012] To achieve the above objective,
[0013] According to one aspect of the present invention, a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof is provided.
[0014] [Chemical Formula 1]
[0015]
[0016] In the above chemical formula 1,
[0017] X is N or CH and;
[0018] R 1 H, halogen, 3-6 cycloalkyl, -NHR 1a , -OR 1b , 6-membered heterocycloalkyl, 5-6-membered heteroaryl, benzo[d][1,3]dioxolyl, CF3, nitro, or NH2, and
[0019] Here, R 1a and R 1b is independently a 3-6 cycloalkyl, substituted C 1-6 Alkyl, unsubstituted, or C 1-6 alkyl-substituted 5-6-membered heteroaryls, or C 1-6 It is an alkoxyphenyl, and
[0020] The above substituted C 1-6 The alkyl group is a 3-6-membered cycloalkyl, a 3-6-membered heterocycloalkyl, or C 1-6 The alkyl group is substituted with a 1 or 2-substituted amino;
[0021] R 2 is H, -COR 2a , -CONR 2b R 2c , halogen, or 5-6-membered heteroaryl, and
[0022] Here, R 2a is H, OH, or C 1-6 It is an alkyloxy, and
[0023] R 2b is C 1-6 Alkyl, 3-6 cycloalkyl, C 1-6 Alkoxyphenyl, unsubstituted or C 1-6 alkyl-substituted 5-6-membered heteroaryls, or methylpiperazinyl-substituted C 1-6 It is alkyl, and
[0024] R 2c is H and or,
[0025] R2b and R 2c They form a 5-6-membered heterocycloalkyl group together with the nitrogen atoms to which they are connected;
[0026] R 3 is CF3, or cyano-substituted C 1-6 It is alkyl;
[0027] R 4 is C 1-6 Alkyl-substituted 5-membered heteroaryl, or C 1-6 C substituted with an alkyl-substituted 6-membered heterocycloalkyl 1-6 It is alkyl;
[0028] R 5 is H, halogen, -NHR 5a , or -OR 5b And,
[0029] Here, R 5a and R 5b C is independently substituted with a 5-6-membered heterocycloalkyl group 1-6 Alkyl, or diC 1-6 C substituted with alkylamino 1-6 It is alkyl;
[0030] However, the above R 1 and R 2 Not all of them are H.
[0031] In addition, the present invention, as shown in the following reaction scheme 1,
[0032] A method for preparing a compound represented by Chemical Formula 1 is provided, comprising the step of reacting a compound represented by Chemical Formula 2 with a compound represented by Chemical Formula 3 to prepare a compound represented by Chemical Formula 1:
[0033] [Reaction Equation 1]
[0034]
[0035] In the above reaction equation, R 1 , R 2 , R 3 , R 4 , and R 5 It is as defined in Chemical Formula 1 of Article 1.
[0036] According to another aspect of the present invention, a pharmaceutical composition for the prevention or treatment of cancer is provided, comprising a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
[0037] According to another aspect of the present invention, a health functional food composition for the prevention or improvement of cancer is provided, comprising a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
[0038] Furthermore, the present invention provides a method for preventing or treating cancer, comprising the step of administering the above pharmaceutical composition in a therapeutically effective amount to a subject in need thereof.
[0039] In addition, the present invention provides a method for preventing or treating cancer comprising the step of administering a compound represented by Formula 1, an isomer thereof, or a pharmaceutically acceptable salt thereof in a therapeutically effective amount to a subject in need thereof.
[0040] Furthermore, the present invention provides a use for the prevention or treatment of cancer of a compound represented by the above formula 1, its isomers, or pharmaceutically acceptable salts thereof. Effects of the invention
[0041] Since the novel RET inhibitory compound according to the present invention or the pharmaceutically acceptable salt thereof exhibits high inhibitory activity against RET kinase and its mutations, it can be usefully used as a pharmaceutical composition for the prevention or treatment of cancer or as a health functional food composition for the prevention or improvement of cancer. Specific details for implementing the invention
[0042] The present invention will be described in detail below.
[0043] The compound according to the present invention is provided according to the first to eighth aspects.
[0044] First aspect:
[0045] In the first embodiment of the present invention,
[0046] The compound according to the present invention may be a compound represented by the following chemical formula 1.
[0047] [Chemical Formula 1]
[0048]
[0049] In the above chemical formula 1,
[0050] X is N or CH and;
[0051] R 1 H, halogen, 3-6 cycloalkyl, -NHR 1a , -OR 1b , 6-membered heterocycloalkyl, 5-6-membered heteroaryl, benzo[d][1,3]dioxolyl, CF3, nitro, or NH2, and
[0052] Here, R 1a and R 1b is independently a 3-6 cycloalkyl, substituted C 1-6 Alkyl, unsubstituted, or C 1-6 alkyl-substituted 5-6-membered heteroaryls, or C 1-6 It is an alkoxyphenyl, and
[0053] The above substituted C 1-6 The alkyl group is a 3-6-membered cycloalkyl, a 3-6-membered heterocycloalkyl, or C 1-6 The alkyl group is substituted with a 1 or 2-substituted amino;
[0054] R 2 is H, -COR 2a , -CONR 2b R 2c , halogen, or 5-6-membered heteroaryl, and
[0055] Here, R 2a is H, OH, or C 1-6 It is an alkyloxy, and
[0056] R 2b is C 1-6 Alkyl, 3-6 cycloalkyl, C 1-6 Alkoxyphenyl, unsubstituted or C 1-6alkyl-substituted 5-6-membered heteroaryls, or C-substituted with methylpiperazinyl 1-6 It is alkyl, and
[0057] R 2c is H and or,
[0058] R 2b and R 2c They form a 5-6-membered heterocycloalkyl group together with the nitrogen atoms to which they are connected;
[0059] R 3 is CF3, or cyano-substituted C 1-6 It is alkyl;
[0060] R 4 is C 1-6 Alkyl-substituted 5-membered heteroaryl, or C 1-6 C substituted with an alkyl-substituted 6-membered heterocycloalkyl 1-6 It is alkyl;
[0061] R 5 is H, halogen, -NHR 5a , or -OR 5b And,
[0062] Here, R 5a and R 5b C is independently substituted with a 5-6-membered heterocycloalkyl group 1-6 Alkyl, or diC 1-6 C substituted with alkylamino 1-6 It is alkyl;
[0063] However, the above R 1 and R 2 Not all of them are H.
[0064] In the second embodiment, the R 1 It may be chloro, and the above R 2 It can be chloro.
[0065] In each of the prior embodiments, the third embodiment is the R 2 -COR 2a , or -CONR 2b R 2c and R 2a , R 2b and R 2cis as defined above.
[0066] The fourth embodiment is, in each of the prior embodiments, R 1a is cyclopropyl, substituted C 1-6 Alkyl, C 1-6 alkyl-substituted 5-membered heteroaryls, or C 1-6 It is an alkoxyphenyl, and
[0067] The above substituted C 1-6 The alkyl group is cyclopropyl, 5-6-membered heterocycloalkyl, or diC 1-6 Substituted with alkylaminos,
[0068] R 1b C is substituted with a 3-6-membered heterocycloalkyl group 1-6 Alkyl, or mono-C 1-6 C substituted with alkylamino 1-6 It is an alkyl.
[0069] The fifth embodiment is, in each of the prior embodiments,
[0070] R 5a C is substituted with a 5-6-membered heterocycloalkyl group 1-6 Alkyl, or diC 1-6 C substituted with alkylamino 1-6 It is alkyl, and
[0071] R 5b C is substituted with a 6-membered heterocycloalkyl group 1-6 It is an alkyl.
[0073] Second side:
[0074] In the first embodiment, Chemical Formula 1 is defined as follows.
[0075] X is N or CH and;
[0076] R 1 Silver H, chloro, cyclopropyl, -NHR 1a , -OR 1b , morpholinyl, pyridyl, thiophenyl, pyrazolyl, pyrimidinyl, oxazolyl, benzo[d][1,3]dioxolyl, CF3, nitro, or NH2, and
[0077] R 1a is cyclopropyl, substituted C1-3 Alkyl, C 1-3 Pyrazolyl substituted with alkyl, or C 1-3 It is an alkoxyphenyl, and
[0078] The above substituted C 1-3 The alkyl group is cyclopropyl, piperidinyl, pyrrolidinyl, or diC 1-3 Substituted with alkylaminos,
[0079] R 1b is C substituted with morpholinyl 1-3 C substituted with alkyl or aziridinyl 1-3 Alkyl, or mono-C 1-3 C substituted with alkylamino 1-3 It is alkyl;
[0080] R 2 is H, -COR 2a , -CONR 2b R 2c , chloro, thiophenyl, or oxazolyl, and
[0081] Here, R 2a is H, OH, or C 1-3 It is an alkyloxy, and
[0082] R 2b is C 1-3 Alkyl, cyclopropyl, C 1-3 Alkoxyphenyl, unsubstituted or C 1-3 Alkyl-substituted pyrazolyl, C 1-3 C substituted with alkyl-substituted isoxazolyl, pyrimidinyl, or methylpiperazinyl 1-3 It is alkyl, and
[0083] R 2c is H and or,
[0084] R 2b and R 2c They form methylpiperazinyl or mopolinyl together with the nitrogen atoms to which they are connected;
[0085] R 3 is CF3, or cyano-substituted C 1-3 It is alkyl;
[0086] R 4 is C 1-3Alkyl-substituted imidazolyl, methylpiperazinyl-substituted C 1-3 It is alkyl;
[0087] R 5 is H, F, -NHR 5a , or -OR 5b And,
[0088] R 5a is C substituted with piperidinyl 1-3 C substituted with alkyl, pyrrolidinyl 1-3 Alkyl, or diC 1-3 C substituted with alkylamino 1-3 It is alkyl, and
[0089] R 5b is C substituted with morpholinyl 1-3 It is alkyl;
[0090] However, the above R 1 and R 2 Not all of them are H.
[0091] In the second embodiment, the R 1 It may be chloro, and the above R 2 It can be chloro.
[0092] In each of the prior embodiments, the third embodiment is the R 2 -COR 2a , or -CONR 2b R 2c and R 2a , R 2b and R 2c is as defined above.
[0094] Third Aspect:
[0095] In the definition of Formula 1 according to all embodiments of all prior aspects,
[0096] R 4 is C 1-6 It is an alkyl-substituted 5-membered heteroaryl, preferably C 1-3 It is an alkyl-substituted imidazolyl, and more preferably a methyl-substituted imidazolyl.
[0098] Fourth Aspect:
[0099] The compound according to the present invention may be a compound represented by the following chemical formula 1A.
[0100] [Chemical Formula 1A]
[0101]
[0102] In the above chemical formula 1A, R 1 , R 2 , and R 5 It is as defined in all preceding aspects and all embodiments.
[0104] Fifth Aspect:
[0105] In the definition of Formula 1 according to all embodiments of all prior aspects, R 4 is C 1-6 C substituted with an alkyl-substituted 6-membered heterocycloalkyl 1-6 It is alkyl, preferably C 1-3 C substituted with an alkyl-substituted 6-membered heterocycloalkyl 1-3 It is alkyl, more preferably methyl substituted with methylpiperazinyl, wherein R 5 is H.
[0107] Sixth Aspect:
[0108] The compound according to the present invention may be a compound represented by the following chemical formula 1B.
[0109] [Chemical Formula 1B]
[0110]
[0111] In the above chemical formula 1B, R 1 , and R 2 It is as defined in all preceding aspects and all embodiments.
[0113] Seventh Aspect:
[0114] In the first embodiment, Chemical Formula 1 is defined as follows.
[0115] X is N or CH and;
[0116] R 1H, chloro, cyclopropylamino, cyclopropylmethylamino, (5-methyl-1H-pyrazole-3-yl)amino, 2-morpholinoethoxy, (2-(piperidin-1-yl)ethyl)amino, 2-(isopropylamino)ethoxy, (2-(pyrrolidin-1-yl)ethyl)amino, 2-(aziridin-1-yl)ethoxy, (4-methoxyphenyl)amino, 2-(dimethylamino)ethyl)amino,
[0117] . , , , , , , ,
[0118] It is cyclopropyl, CF3, nitro, or NH2, and
[0119] R 2 is H, chloro, CHO, COOH, COOMe,
[0120] , , , , , , , , , , , , ,
[0121] or COOEt,
[0122] R 3 is CF3, or And,
[0123] R 4 Is , or And,
[0124] R 5 Is , , or F and,
[0125] However, the above R 1 and R 2 Not all of them are H.
[0126] In the second embodiment, the R 1 It may be chloro, and the above R 2 It can be chloro.
[0127] In each of the prior embodiments, the third embodiment is the R 2 -COR 2a , or -CONR 2b R 2c and R 2a , R 2b and R 2c is as defined above.
[0129] Eighth Aspect:
[0130] The compound represented by the above chemical formula 1 may be any one selected from the group of compounds below.
[0131] <1> 6-chloro-3-((2-methyl-5-((3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylate
[0132] <2> 6-chloro-3-((5-((3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)carbamoyl)-4-fluoro-2-methylphenyl)ethinyl)imidazo[1,2-b]pyridazine-2-carboxylate
[0133] <3> Ethyl 6-(cyclopropylamino)-3-((2-methyl-5-((3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylate
[0134] <4> Ethyl 6-((cyclopropylmethyl)amino)-3-((2-methyl-5-((3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylate
[0135] <5> Ethyl 6-((5-methyl-1H-pyrazole-3-yl)amino)-3-((2-methyl-5-((3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylate
[0136] <6> Ethyl 3-((5-((3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)carbamoyl)-4-fluoro-2-methylphenyl)ethynyl)-6-(2-morpholinoethoxy)imidazo[1,2-b]pyridazine-2-carboxylate
[0137] <7> ethyl 3-((5-((3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)carbamoyl)-2-methyl-4-((2-(piperidine-1-yl)ethyl)amino)phenyl)ethynyl)-6-((2-(piperidine-1-yl)ethyl)amino)imidazo[1,2-b]pyridazine-2-carboxylate
[0138] <8> 3-((5-((3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)carbamoyl)-2-methyl-4-(2-(piperidine-1-yl)ethoxy)phenyl)ethynyl)-6-(2-morpholinoethoxy)imidazo[1,2-b]pyridazine-2-carboxylic acid
[0139] <9> Ethyl 6-chloro-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylate
[0140] <10> 6-chloro-N-isopropyl-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxamide
[0141] <11> 6-chloro-N-cyclopropyl-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxamide
[0142] <12> 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxamide
[0143] <13> 6-chloro-N-(4-methoxyphenyl)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxamide
[0144] <14> 3-((6-chloro-2-formylimidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0145] <15> 6-(2-(isopropylamino)ethoxy)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylic acid
[0146] <16> N-isopropyl-6-(2-(isopropylamino)ethoxy)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxamide
[0147] <17> 5-((6-chloroimidazo[1,2-b]pyridazine-3-yl)ethynyl)-N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-fluoro-4-methylbenzamide
[0148] <18> 5-((6-chloroimidazo[1,2-b]pyridazine-3-yl)ethynyl)-N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-4-methyl-2-((2-(piperidine-1-yl)ethyl)amino)benzamide
[0149] <19> 5-((6-chloroimidazo[1,2-b]pyridazine-3-yl)ethynyl)-N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-((2-(diethylamino)ethyl)amino)-4-methylbenzamide
[0150] <20> N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-4-methyl-2-((2-(pyrrolidin-1-yl)ethyl)amino)-5-((6-((2-(pyrrolidin-1-yl)ethyl)amino)imidazo[1,2-b]pyridazine-3-yl)ethynyl)benzamide
[0151] <21> 5-((6-(2-(aziridin-1-yl)ethoxy)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-fluoro-4-methylbenzamide
[0152] <22> N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-fluoro-5-((6-(2-(isopropylamino)ethoxy)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methylbenzamide
[0153] <23> N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-fluoro-4-methyl-5-((6-(2-morpholinoethoxy)imidazo[1,2-b]pyridazine-3-yl)ethynyl)benzamide
[0154] <24> 3-((6-chloroimidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0155] <25> 3-((6-(2-(aziridin-1-yl)ethoxy)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0156] <26> 3-((6-(2-(isopropylamino)ethoxy)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0157] <27> 4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(2-morpholinoethoxy)imidazo[1,2-b]pyridazine-3-yl)ethynyl)benzamide
[0158] <28> 3-((6-((4-methoxyphenyl)amino)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0159] <29> 4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-morpholinoimidazo[1,2-b]pyridazine-3-yl)ethynyl)benzamide
[0160] <30> ethyl 6-((2-(dimethylamino)ethyl)amino)-3-((2-methyl-5-((3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylate
[0161] <31> 6-chloro-N-(1-methyl-1H-pyrazol-4-yl)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxamide
[0162] <32> 3-((6-chloro-2-(4-methylpiperazine-1-carbonyl)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine)-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0163] <33> 6-(2-(isopropylamino)ethoxy)-N-(1-methyl-1H-pyrazole-4-yl)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl))methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxamide
[0164] <34> 3-((6-(2-(isopropylamino)ethoxy)-2-(4-methylpiperazine-1-carbonyl)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0165] <35> 3-((2,6-dichloroimidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)benzamide
[0166] <36> N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-5-((2,6-dichloroimidazo[1,2-a]pyridine-3-yl)ethynyl)-2-fluoro-4-methylbenzamide
[0167] <37> 5-((2-chloro-6-(pyridin-3-yl)imidazoo[1,2-a]pyridin-3-yl)ethynyl)-N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-fluoro-4-methylbenzamide
[0168] <38> 3-((2-chloro-6-(pyridin-3-yl)imidazoo[1,2-a]pyridin-3-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)benzamide
[0169] <39> 3-((2-chloro-6-(thiophene-3-yl)imidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)benzamide
[0170] <40> 3-((2-chloro-6-(thiophene-2-yl)imidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)benzamide
[0171] <41> 3-((2-chloro-6-(1H-pyrazole-3-yl)imidazo[1,2-a]pyridin-3-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)benzamide
[0172] <42> 3-((2,6-di(thiophene-2-yl)imidazoz[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)benzamide
[0173] <43> 3-((2-chloro-6-(pyrimidine-5-yl)imidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0174] <44> 3-((2-chloro-6-cyclopropylimidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0175] <45> 3-((2-chloro-6-(furan-3-yl)imidazo[1,2-a]pyridin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0176] <46> 3-((2-(furan-2-yl)-6-(furan-3-yl)imidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0177] <47> 3-((6-(benzo[d][1,3]dioxol-5-yl)-2-chloroimidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0178] <48> methyl 3-((2-methyl-5-((3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylate
[0179] <49> 4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((2-(morpholine-4-carbonyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-3-yl)ethynyl)benzamide
[0180] <50> N-(1-methyl-1H-pyrazol-4-yl)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide
[0181] <51> 3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-N-(5-methylisoxazole-3-yl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide
[0182] <52> 3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-N-(1H-pyrazol-3-yl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide
[0183] <53> 3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-N-(pyrimidine-4-yl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide
[0184] <54> ethyl 3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-6-nitromidazo[1,2-a]pyridine-2-carboxylate
[0185] <55> 3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-6-nitromidazo[1,2-a]pyridine-2-carboxylic acid
[0186] <56> Ethyl 6-amino-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-a]pyridine-2-carboxylate
[0187] <57> 5-((2-chloro-6-(1H-pyrazole-4-yl)imidazo[1,2-a]pyridin-3-yl)ethynyl)-N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-fluoro-4-methylbenzamide
[0188] <58> 3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-N-(2-(4-methylpiperazine-1-yl)ethyl)-6-nitromidazo[1,2-a]pyridine-2-carboxamide.
[0189] In the present invention, the term "alkyl" comprises straight-chain or branched-chain saturated hydrocarbon residues unless otherwise specified. For example, "C 1-6 "Alkyl" refers to an alkyl group with a skeleton of 1 to 6 carbons. Specifically, C 1-6 Alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, n-pentyl, i-pentyl, t-pentyl, sec-pentyl, neopentyl, hexyl, etc.
[0190] The term "cycloalkyl" means a cyclic hydrocarbon residue forming a ring as a saturated hydrocarbon residue, unless otherwise specified, and "3-6-cycloalkyl" means a cyclic hydrocarbon residue containing 3 to 6 carbons as ring atoms.
[0191] The term “heterocycloalkyl” means a monovalent saturated residue comprising one to three rings containing one or more heteroatoms selected from N, O, or S (e.g., 1-5, 1-4, 1-3, 1-2, 1). It may be bicyclic or tricyclic comprising two or three rings, wherein these two or three rings may be bridged, fused, or spiral heterocycloalkyls. In the case of multiple rings, heteroatoms may be present in all rings or in some rings.
[0192] The term "aryl" refers to an aromatic radical in which a single ring or two or three hydrocarbon aromatic rings are fused, and C 6-10 Aryl refers to an aromatic ring compound containing 6 to 10 carbons, including phenyl or naphthyl.
[0193] The term “heteroaryl” means an aromatic radical having one or more aromatic rings (the remaining ring atoms are C) containing one or more heteroatoms selected from N, O, or S as ring atoms (e.g., 1-5, 1-4, 1-3, 1-2, 1) unless otherwise specified. In the case of multiple rings, the heteroatoms may be present in all rings or in some rings.
[0194] The term “alkoxy” refers to a substituent in which an alkyl group is connected through an oxygen atom, and C 1-10 Alkoxy is C 1-10 It refers to a substituent in which an alkyl group is connected to an oxygen atom and substituted through oxygen.
[0195] The term “halogen” refers to halogen atoms such as F, Cl, Br, and I, and when it is said to be “halogen” substituted, it means that it has been substituted with one or more halogen atoms. The halogen atoms being substituted can be selected from a range of 1 to 5.
[0196] The term "pharmaceuticalally acceptable salt" means a salt that is pharmaceutically acceptable as a salt formed by ionic bonding with a compound containing a carboxylic acid or amine functional group.
[0197] The compound represented by Formula 1 of the present invention can be used in the form of a pharmaceutically acceptable salt, and as the salt, an acid addition salt formed by a pharmaceutically acceptable free acid is useful. The acid addition salt is obtained from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromide, hydroiodide, nitrous acid, phosphoric acid, etc., aliphatic mono and dicarboxylates, phenyl-substituted alkanoates, hydroxyalkanoates and alkandioates, aromatic acids, aliphatic and aromatic sulfonic acids, etc., non-toxic organic acids such as trifluoroacetic acid, acetate, benzoic acid, citric acid, lactic acid, maleic acid, gluconic acid, methanesulfonic acid, 4-toluenesulfonic acid, tartaric acid, fumaric acid, etc. These types of pharmaceutically non-toxic salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphate chloride, bromides, iodides, fluorides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caprates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, malieates, butyne-1,4-dioate, hexane-1,6-dioate, benzoates, chlorobenzoates, methyl benzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, and phthalates. Terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, Includes hydroxybutyrate, glycolate, maleate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, etc.
[0198] The acid addition salt according to the present invention can be prepared by conventional methods, for example, by dissolving a derivative of Formula 1 in an organic solvent such as methanol, ethanol, acetone, methylene chloride, acetonitrile, etc., adding an organic acid or an inorganic acid to produce a precipitate, filtering and drying it, or by vacuum distilling the solvent and excess acid, drying it, and crystallizing it under an organic solvent.
[0199] In addition, pharmaceutically acceptable metal salts can be produced using a base. Alkali metal or alkaline earth metal salts are obtained, for example, by dissolving a compound in an excess amount of alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and evaporating and drying the filtrate. In this case, it is pharmaceutically suitable to produce sodium, potassium, or calcium salts as the metal salts. In addition, the corresponding salts are obtained by reacting the alkali metal or alkaline earth metal salt with a suitable base salt (e.g., silver nitrate).
[0200] Another aspect of the present invention is, as shown in the following reaction scheme 1,
[0201] A method for preparing a compound represented by Chemical Formula 1 according to claim 1 is provided, comprising the step of reacting a compound represented by Chemical Formula 2 with a compound represented by Chemical Formula 3 to prepare a compound represented by Chemical Formula 1.
[0202] [Reaction Equation 1]
[0203]
[0204] In the above reaction equation, R 1 , R 2 , R 3 , R 4 , and R 5 It is as defined in Chemical Formula 1 of Article 1.
[0205] In the above reaction scheme, the reaction of Chemical Formula 2 and Chemical Formula 3 is a coupling reaction under metal catalyst conditions, and the reaction conditions are carried out under normal organic solvent conditions and include [(cinnamyl)PdCl]2, cBRIDP, TPGS / H2O, Et3N, etc.
[0206] The reaction temperature is not particularly limited, but can be carried out in the range of 0 to 100°C, 10 to 50°C, and at room temperature.
[0207] Another aspect of the present invention provides a pharmaceutical composition for the prevention or treatment of cancer containing a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
[0208] At this time, the above cancer is pseudomyxoma, intrahepatic cholangiocarcinoma, hepatoblastoma, liver cancer, thyroid cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, mycosis fungoides, acute myeloid leukemia, acute lymphoblastic leukemia, basal cell carcinoma, ovarian epithelial carcinoma, ovarian germ cell carcinoma, male breast cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colorectal cancer, chronic myeloid leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, ampulla of Vater cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, rhinosinus cancer, tongue cancer, astrocytoma, small intestine cancer, meningioma, esophageal cancer, glioma, renal pelvis cancer, kidney cancer, heart cancer, duodenal cancer, malignant soft tissue cancer, malignant bone cancer, malignant lymphoma, malignant mesothelioma, malignant melanoma, One or more types selected from the group consisting of ocular cancer, vulvar cancer, ureteral cancer, urethral cancer, cancer of unknown primary site, gastric lymphoma, gastric cancer, gastric carcinoid tumor, gastrointestinal stromal cancer, Wilms' cancer, breast cancer, penile cancer, pharyngeal cancer, gestational trophoblastic disease, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, metastatic bone cancer, metastatic brain cancer, mediastinal cancer, rectal cancer, vaginal cancer, spinal cord cancer, acoustic neuroma, pancreatic cancer, salivary gland cancer, Kaposi sarcoma, Paget's disease, tonsil cancer, squamous cell carcinoma, lung cancer, skin cancer, anal cancer, rhabdomyosarcoma, laryngeal cancer, pleural cancer, and thymic cancer.
[0209] In addition, the above compound or a pharmaceutically acceptable salt thereof can inhibit RET and RET mutations, and through such inhibition, possesses preventive, remedial, or therapeutic activity against cancer, wherein the RET mutations may include V804M, V804L, G810R, G810S, G810C, G810A, RET-CCDC6, RET-NCOA4, RET-KIF5B, RET-RET(V804M)-KIF5B, M918T / V804M / G810S, M918T / V804M / G810C, etc., and the cancer is the same as previously described.
[0210] The above compound or a pharmaceutically acceptable salt thereof has growth inhibitory activity against mutant cancer cells, and the cells express RET and RET mutations as described above, and in one embodiment, may be cancer cells expressing one of V804M, V804L, G810R, G810S, G810C, G810A, M918T / V804M / G810S, M918T / V804M / G810C, etc.
[0211] In addition, a pharmaceutical composition for the prevention or treatment of cancer containing a compound represented by the above chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient may be administered as an individual treatment or administered in combination with other anticancer agents currently in use.
[0212] In addition, a pharmaceutical composition for the prevention or treatment of cancer containing a compound represented by the above chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient can enhance the anticancer effect by co-administering it with an anticancer agent.
[0213] The compound represented by Chemical Formula 1 above or its pharmaceutically acceptable salt may be administered in various oral and parenteral formulations during clinical administration. When formulating, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid formulations for oral administration include tablets, pills, powders, granules, and capsules, and these solid formulations are prepared by mixing at least one excipient, e.g., starch, calcium carbonate, sucrose or lactose, gelatin, etc., with one or more compounds. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, oral liquids, emulsions, and syrups; in addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients, such as humectants, sweeteners, flavorings, and preservatives. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, and emulsions. Non-aqueous solvents and suspension agents may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleates.
[0214] A pharmaceutical composition having a compound represented by the above chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient may be administered parenterally, and parenteral administration is by a method of injecting subcutaneously, intravenously, intramuscularly, or intrathoracically.
[0215] At this time, in order to formulate a parenteral administration formulation, a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof may be mixed with water together with a stabilizer or a buffer to prepare a solution or suspension, and may be prepared in an ampoule or vial unit dosage form. The composition may be sterilized and / or contain adjuvants such as preservatives, stabilizers, hydrating agents or emulsification promoters, salts and / or buffers for osmotic pressure regulation, and other therapeutically useful substances, and may be formulated according to conventional mixing, granulation, or coating methods.
[0216] Oral dosage forms include, for example, tablets, pills, hard / soft capsules, liquids, suspensions, emulsifiers, syrups, granules, elixirs, troches, etc., and these dosage forms contain, in addition to the active ingredient, diluents (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine) and lubricants (e.g., silica, talc, stearic acid and its magnesium or calcium salts and / or polyethylene glycol). Tablets may contain binders such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidine, and, in some cases, disintegrants or boiling mixtures such as starch, agar, alginic acid or its sodium salts and / or absorbents, coloring agents, flavoring agents, and sweeteners.
[0217] Another aspect of the present invention provides a health functional food for the prevention or improvement of cancer containing a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. In this case, the cancer is the same as previously described.
[0218] The compound represented by Formula 1 according to the present invention may be added directly to food or used together with other food or food ingredients, and may be used appropriately according to conventional methods. The amount of the active ingredient may be appropriately determined according to its purpose of use (for prevention or improvement). Generally, the amount of the compound in the health food may be added in an amount of 0.1 to 90 parts by weight of the total weight of the food. However, in the case of long-term consumption for the purpose of health and hygiene or for health control, the amount may be less than the above range, and the active ingredient may be used in an amount greater than the above range as there is no problem in terms of safety.
[0219] Another aspect of the present invention provides a method for preventing, improving, or treating cancer, comprising the step of administering a pharmaceutical composition or a health functional food containing a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient to a person in need.
[0220] Another aspect of the present invention provides the use or application of a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof in the prevention, improvement, or treatment of cancer.
[0221] The compound represented by Formula 1 of the present invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof is administered in a “pharmaceutically effective amount.” In the present invention, the term “pharmaceutically effective amount” means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment or improvement, and the effective dose level may be determined based on factors including individual type and severity, age, sex, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. For example, effective amounts include 0.001 mg / kg to 1000 mg / kg, 0.01 mg / kg to 100 mg / kg, 0.1 to 20 mg / kg, or 0.1 to 500 mg / kg. The amount of the pharmaceutical composition of the present invention may be selected and administered by a person skilled in the art within an appropriate range.
[0222] The present invention will be explained in detail below through examples and experimental examples.
[0223] However, the following examples and experimental examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples and experimental examples.
[0224] <Preparation Example 1> Preparation of 3-ethynyl-4-methyl-N-(3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)benzamide
[0225]
[0226] Methyl 4-methyl-3-((trimethylsilyl)ethynyl)benzoate (1.21 mmol, 1 equivalent), 3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)aniline (0.8 equivalents), and potassium tertiary butoxide (0.97 mmol, 2.5 equivalents) were dissolved in tetrahydrofuran, and the reaction mixture was stirred at 25°C for 12 hours. After the reaction was completed, the crude material was diluted with water (10 ml) and extracted with EtOAc (10 ml x 3 times). The organic layer was concentrated under reduced pressure and purified by column chromatography (0-5% MeOH:DCM) to obtain the desired product, the compound of Preparation Example 1.
[0227] Yield 26%; 1 H NMR (600 MHz, CDCl3) δ 8.26 (d, J = 7.8 Hz, 1H), 7.93 (s, 1H), 7.81 (s, 1H), 7.57 (s, 1H), 7.25 (s, 1H), 7.09 (d, J = 16.3 Hz, 2H), 3.33 (s, 1H), 2.53 (s, 3H), 2.31 (s, 3H), 1.79 (s, 6H).
[0228] <Preparation Example 2> Preparation of N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-5-ethynyl-2-fluoro-4-methylbenzamide
[0229]
[0230] The compound of Preparation Example 2 was obtained by making it similar to Preparation Example 1.
[0231] Yield 59%; 1 H NMR (600 MHz, CDCl3) δ 8.19 (d, J = 2.1 Hz, 1H), 8.08 (d, J = 1.9 Hz, 1H), 8.04 (d, J = 8.5, 2.0 Hz, 1H), 7.90 (d, J = 8.0, 1.9 Hz, 1H), 7.69 (d, J = 8.5 Hz, 1H), 7.47 (d, J= 8.1 Hz, 1H), 4.52 (s, 1H), 3.55 (s, 2H), 2.46 (s, 3H), 2.44 - 2.16 (m, 8H), 2.15 (s, 3H).
[0232] <Preparation Example 3> Preparation of 3-ethynyl-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0233]
[0234] The compound of Preparation Example 3 was obtained by making it similar to Preparation Example 1.
[0235] Yield 59%; 1 H NMR (600 MHz, CDCl3) δ 8.19 (d, J = 2.1 Hz, 1H), 8.08 (d, J = 1.9 Hz, 1H), 8.04 (d, J = 8.5, 2.0 Hz, 1H), 7.90 (d, J = 8.0, 1.9 Hz, 1H), 7.69 (d, J = 8.5 Hz, 1H), 7.47 (d, J = 8.1 Hz, 1H), 4.52 (s, 1H), 3.55 (s, 2H), 2.46 (s, 3H), 2.44 - 2.16 (m, 8H), 2.15 (s, 3H).
[0236] <Example 1> Preparation of Ethyl 6-Chloro-3-((2-methyl-5-((3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylate
[0237]
[0238] Preparation of Compound 6:
[0239] NaHCO3 (651.16 mg, 7.75 mmol, 2 equivalents) and ethyl 3-bromo-2-oxopropionate (831.39 mg, 4.26 mmol, 1.2 equivalents) were sequentially added to a stirred solution of 6-chloropyridazine-3-amine (500 mg, 3.87 mmol, 1 equivalent) dissolved in 10 ml of dioxane. The mixture was stirred at 100°C for 12 hours. After the reaction was complete, the mixture was cooled to room temperature, poured into an Erlenmeyer flask diluted with water, and extracted with ethyl acetate. It was then dried and concentrated with anhydrous sodium sulfate to obtain a crude black colloid, and the product was purified by silica gel column chromatography to obtain Compound 6.
[0240] Yield 60%; 1 H NMR (600 MHz, CDCl3) δ 8.50 - 8.40 (m, 1H), 7.98 (d, J = 9.6 Hz, 1H), 7.15 (d, J = 9.6 Hz, 1H), 4.48 (q, J = 7.1 Hz, 2H), 1.45 (t, J = 7.1 Hz, 3H).
[0241] Preparation of Compound 7:
[0242] Molecular iodine (2248 mg, 8.88 mmol, 1 equivalent) and AgOTf (2266 mg, 8.88 mmol, 1 equivalent) were added to a solution of Compound 6 (2000 mg, 8.88 mmol, 1 equivalent) dissolved in DCM (20 ml). Subsequently, the reaction mixture was stirred at room temperature for 16 hours. Afterward, the mixture was diluted with EtOAc (50 ml), and the resulting mixture was passed through a Celite pad. The filtrate was collected and concentrated under reduced pressure. The crude material was purified by column chromatography (0-30% EtOAc:Hex) to obtain Compound 7.
[0243] Yield 40%; 1H NMR (600 MHz, CDCl3) δ 7.95 (d, J = 9.5 Hz, 1H), 7.21 (d, J = 9.5 Hz, 1H), 4.52 (q, J = 7.1 Hz, 2H), 1.49 (t, J = 7.1 Hz, 3H).
[0244] Preparation of compound 1a:
[0245] The compound prepared in Preparation Example 1 (1.13 mmol, 1 equivalent), [(cinnamyl)PdCl]2 (0.0005 mmol, 0.0005 equivalents), and cBRIDP (0.003 mmol, 0.003 equivalents) were added to 2 wt% TPGS / H2O (0.2 ml) using a syringe in an oven-dried 10 ml round-bottom flask. After emptying the flask and refilling it with argon three times, ethyl 6-chloro-3-iodoimidazo[1,2-b]pyridazine-2-carboxylate (1.36 mmol, 1.2 equivalents), Et3N (2.27 mmol, 2 equivalents), and the reaction mixture were heated at 45°C for 8 hours while vigorously stirring, and then cooled to room temperature after the reaction was complete. The mixture was extracted with EtOAc (10 ml x 3). The organic layer was dried with anhydrous Na2SO4 and the solvent was removed under vacuum. The crude product was purified by flash column chromatography (0-5% MeOH:DCM) to obtain compound 1a.
[0246] <Example 2> Preparation of 6-chloro-3-((5-((3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)carbamoyl)-4-fluoro-2-methylphenyl)ethinyl)imidazo[1,2-b]pyridazine-2-carboxylate
[0247] Compound 1b was obtained in a manner similar to Example 1.
[0248] <Example 3> Preparation of Ethyl 6-(cyclopropylamino)-3-((2-methyl-5-((3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylate
[0249]
[0250] A stirred solution of Compound 1a (0.03 mmol, 1 equivalent) prepared in Example 1, cyclopropanamine (0.04 mmol, 1.2 equivalents), and potassium fluoride (0.36 mmol, 10 equivalents) dissolved in DMSO (0.5 ml) was stirred overnight at 100°C. After the reaction was complete, the mixture was cooled and diluted with water. The mixture was extracted with EtOAc (10 ml x 3). The organic layer was dried with anhydrous Na2SO4, and the solvent was removed under vacuum. The crude product was purified by flash column chromatography (0-5% MeOH:DCM) to obtain Compound 1c.
[0251] <Example 4> Preparation of Ethyl 6-((cyclopropylmethyl)amino)-3-((2-methyl-5-((3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylate
[0252] Compound 1d was obtained in a manner similar to Example 3.
[0253] <Example 5> Preparation of Ethyl 6-((5-methyl-1H-pyrazole-3-yl)amino)-3-((2-methyl-5-((3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylate
[0254] Compound 1e was obtained in a manner similar to Example 3.
[0255] <Example 6> Preparation of Ethyl 3-((5-((3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)carbamoyl)-4-fluoro-2-methylphenyl)ethynyl)-6-(2-morpholinoethoxy)imidazo[1,2-b]pyridazine-2-carboxylate
[0256]
[0257] A stirred solution of 2-morpholinoethanol (0.03 mmol, 2 equivalents) dissolved in DMF (0.5 ml) was cooled to 0°C, and then NaH (0.03 mmol, 2 equivalents) was added. After stirring for 30 minutes, Compound 1b (0.01 mmol, 1 equivalent) prepared in Example 2 was added, and the mixture was stirred at room temperature for 2 hours. After the reaction was complete, the mixture was poured onto crushed ice and diluted with EtOAc (10.0 ml). The mixture was extracted with EtOAc (10 ml x 3). The organic layer was dried with anhydrous Na2SO4, and the solvent was removed under vacuum. The crude product was purified by flash column chromatography to obtain Compound 1f.
[0258] <Example 7> Preparation of Ethyl 3-((5-((3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)carbamoyl)-2-methyl-4-((2-(piperidin-1-yl)ethyl)amino)phenyl)ethynyl)-6-((2-(piperidin-1-yl)ethyl)amino)imidazo[1,2-b]pyridazine-2-carboxylate
[0259] 1 g of the compound was obtained in a manner similar to Example 3.
[0260] <Example 8> Preparation of 3-((5-((3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)carbamoyl)-2-methyl-4-(2-(piperidine-1-yl)ethoxy)phenyl)ethynyl)-6-(2-morpholinoethoxy)imidazo[1,2-b]pyridazine-2-carboxylic acid
[0261]
[0262] A stirred solution of 2-morpholinoethanol (0.03 mmol, 2 equivalents) dissolved in DMF (0.5 ml) was cooled to 0°C, and then NaH (0.03 mmol, 2 equivalents) was added. After stirring for 30 minutes, compound 1b (0.01 mmol, 1 equivalent) prepared in Example 2 was added, and the mixture was stirred at room temperature for 2 hours. After the reaction was complete and all of compound 1b had disappeared, the mixture was vacuumed to remove the organic solvent, and a 1M aqueous hydrogen chloride solution was added dropwise until the pH reached 2, and the solvent was removed under vacuum. Compound 1h of Example 8, the main product, and compound 1f of Example 6, a small amount of byproduct, were obtained, and compound 1h was obtained by purification using flash column chromatography.
[0263] <Example 9> Preparation of Ethyl 6-Chloro-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylate
[0264] Compound 1i was obtained by making it similar to Example 1.
[0265] <Example 10> Preparation of 6-chloro-N-isopropyl-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxamide
[0266]
[0267] A solution of compound 1i (0.07 mmol, 1 equivalent) prepared in Example 9 dissolved in tetrahydrofuran was stirred at 0°C. After adding trimethylaluminum (0.93 mmol, 12 equivalents), propane-2-amine was added to obtain compound 1j.
[0268] <Example 11> Preparation of 6-chloro-N-cyclopropyl-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethinyl)imidazo[1,2-b]pyridazine-2-carboxamide
[0269] Compound 1k was obtained in a manner similar to Example 10.
[0270] <Example 12> Preparation of 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxamide
[0271] 1 liter of compound was obtained in a manner similar to Example 10.
[0272] <Example 13> Preparation of 6-chloro-N-(4-methoxyphenyl)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethinyl)imidazo[1,2-b]pyridazine-2-carboxamide
[0273] Compound 1m was obtained in a manner similar to Example 10.
[0274] <Example 14> Preparation of 3-((6-chloro-2-formylimidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0275]
[0276] A solution of 30 mg of compound 1i prepared in Example 9 dissolved in tetrahydrofuran (1 mL) was cooled to -78°C, and an excess amount of DIBAL-H solution was slowly added dropwise while confirming the reduction reaction by TLC. After confirming that all of compound 1i had disappeared, the reaction solution was dropped with a saturated aqueous NH4Cl solution to eliminate the reduction reactivity, and then extracted with EtOAc to obtain compound 1n. Compound 1n was obtained by purification using flash column chromatography.
[0277] <Example 15> Preparation of 6-(2-(isopropylamino)ethoxy)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethinyl)imidazo[1,2-b]pyridazine-2-carboxylic acid
[0278] Compound 1o was obtained in a manner similar to Example 8.
[0279] <Example 16> Preparation of N-isopropyl-6-(2-(isopropylamino)ethoxy)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxamide
[0280] Compound 1p was obtained in a manner similar to Example 6.
[0281] <Example 17> Preparation of 5-((6-chloroimidazo[1,2-b]pyridazine-3-yl)ethynyl)-N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-fluoro-4-methylbenzamide
[0282]
[0283] Compound 9 was prepared in a manner similar to the preparation of Compound 7 in Example 1.
[0284] In addition, compound 1q was obtained in a manner similar to Example 1.
[0285] <Example 18> Preparation of 5-((6-chloroimidazo[1,2-b]pyridazine-3-yl)ethynyl)-N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-4-methyl-2-((2-(piperidine-1-yl)ethyl)amino)benzamide
[0286] Compound 1r was obtained in a manner similar to Example 3.
[0287] <Example 19> Preparation of 5-((6-chloroimidazo[1,2-b]pyridazine-3-yl)ethynyl)-N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-((2-(diethylamino)ethyl)amino)-4-methylbenzamide
[0288] Compound 1s was obtained in a manner similar to Example 3.
[0289] <Example 20> Preparation of N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-4-methyl-2-((2-(pyrrolidin-1-yl)ethyl)amino)-5-((6-((2-(pyrrolidin-1-yl)ethyl)amino)imidazo[1,2-b]pyridazine-3-yl)ethynyl)benzamide
[0290] Compound 1 ton was obtained in a manner similar to Example 3.
[0291] <Example 21> Preparation of 5-((6-(2-(aziridin-1-yl)ethoxy)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-fluoro-4-methylbenzamide
[0292] Compound 1u was obtained in a manner similar to Example 6.
[0293] <Example 22> Preparation of N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-fluoro-5-((6-(2-(isopropylamino)ethoxy)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methylbenzamide
[0294] Compound 1v was obtained in a manner similar to Example 6.
[0295] <Example 23> Preparation of N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-fluoro-4-methyl-5-((6-(2-morpholinoethoxy)imidazo[1,2-b]pyridazine-3-yl)ethynyl)benzamide
[0296] Compound 1w was obtained in a manner similar to Example 6.
[0297] <Example 24> Preparation of 3-((6-chloroimidazo[1,2-b]pyridazine-3-yl)ethinyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0298] Compound 1x was obtained by making it similar to Example 1.
[0299] <Example 25> Preparation of 3-((6-(2-(aziridin-1-yl)ethoxy)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0300] Compound 1y was obtained in a manner similar to Example 6.
[0301] <Example 26> Preparation of 3-((6-(2-(isopropylamino)ethoxy)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0302] Compound 1z was obtained in a manner similar to Example 6.
[0303] <Example 27> Preparation of 4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(2-morpholinoethoxy)imidazo[1,2-b]pyridazine-3-yl)ethynyl)benzamide
[0304] Compound 1aa was obtained in a manner similar to Example 6.
[0305] <Example 28> Preparation of 3-((6-((4-methoxyphenyl)amino)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0306] Compound 1ab was obtained in a manner similar to Example 3.
[0307] <Example 29> Preparation of 4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-morpholinoimidazo[1,2-b]pyridazine-3-yl)ethynyl)benzamide
[0308] Compound 1ac was obtained in a manner similar to Example 3.
[0309] <Example 30> Preparation of Ethyl 6-((2-(dimethylamino)ethyl)amino)-3-((2-methyl-5-((3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylate
[0310] Compound 1ad was obtained in a manner similar to Example 3.
[0311] <Example 31> Preparation of 6-chloro-N-(1-methyl-1H-pyrazol-4-yl)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxamide
[0312] Compound 1ae was obtained in a manner similar to Example 10.
[0313] <Example 32> Preparation of 3-((6-chloro-2-(4-methylpiperazine-1-carbonyl)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine)-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0314] Compound 1af was obtained in a manner similar to Example 10.
[0315] <Example 33> Preparation of 6-(2-(isopropylamino)ethoxy)-N-(1-methyl-1H-pyrazole-4-yl)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl))methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethinyl)imidazo[1,2-b]pyridazine-2-carboxamide
[0316] Compound 1ag was obtained in a manner similar to Example 6.
[0317] <Example 34> Preparation of 3-((6-(2-(isopropylamino)ethoxy)-2-(4-methylpiperazine-1-carbonyl)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0318] Compound 1ah was obtained in a manner similar to Example 6.
[0319] <Example 35> Preparation of 3-((2,6-dichloroimidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)benzamide
[0320] Compound 2a was obtained in a manner similar to Example 1.
[0321] <Example 36> Preparation of N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-5-((2,6-dichloroimidazo[1,2-a]pyridine-3-yl)ethynyl)-2-fluoro-4-methylbenzamide
[0322] Compound 2b was obtained in a manner similar to Example 1.
[0323] <Example 37> Preparation of 5-((2-chloro-6-(pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)ethynyl)-N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-fluoro-4-methylbenzamide
[0324] Compound 2c was obtained in a manner similar to Example 1.
[0325] <Example 38> Preparation of 3-((2-chloro-6-(pyridin-3-yl)imidazoz[1,2-a]pyridin-3-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)benzamide
[0326] Compound 2d was obtained in a manner similar to Example 1.
[0327] <Example 39> Preparation of 3-((2-chloro-6-(thiophene-3-yl)imidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)benzamide
[0328] Compound 2e was obtained in a manner similar to Example 1.
[0329] <Example 40> Preparation of 3-((2-chloro-6-(thiophene-2-yl)imidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)benzamide
[0330] Compound 2f was obtained in a manner similar to Example 1.
[0331] <Example 41> Preparation of 3-((2-chloro-6-(1H-pyrazole-3-yl)imidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)benzamide
[0332] 2g of compound was obtained in a manner similar to Example 1.
[0333] <Example 42> Preparation of 3-((2,6-di(thiophene-2-yl)imidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)benzamide
[0334] Compound 2h was obtained in a manner similar to Example 1.
[0335] <Example 43> Preparation of 3-((2-chloro-6-(pyrimidine-5-yl)imidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0336] Compound 2i was obtained in a manner similar to Example 1.
[0337] <Example 44> Preparation of 3-((2-chloro-6-cyclopropylimidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0338] Compound 2j was obtained in a manner similar to Example 1.
[0339] <Example 45> Preparation of 3-((2-chloro-6-(furan-3-yl)imidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0340] Compound 2k was obtained in a manner similar to Example 1.
[0341] <Example 46> Preparation of 3-((2-(furan-2-yl)-6-(furan-3-yl)imidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0342] Compound 2l was obtained in a manner similar to Example 1.
[0343] <Example 47> Preparation of 3-((6-(benzo[d][1,3]dioxol-5-yl)-2-chloroimidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
[0344] Compound 2m was obtained in a manner similar to Example 1.
[0345] <Example 48> Preparation of Methyl 3-((2-methyl-5-((3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylate
[0346] Compound 2q was obtained in a manner similar to Example 1.
[0347] <Example 49> Preparation of 4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((2-(morpholine-4-carbonyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-3-yl)ethynyl)benzamide
[0348] Compound 2r was obtained in a manner similar to Example 1.
[0349] <Example 50> Preparation of N-(1-methyl-1H-pyrazol-4-yl)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide
[0350] Compound 2s was obtained in a manner similar to Example 1.
[0351] <Example 51> Preparation of 3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-N-(5-methylisoxazole-3-yl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide
[0352] Compound 2t was obtained in a manner similar to Example 1.
[0353] <Example 52> Preparation of 3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-N-(1H-pyrazol-3-yl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide
[0354] Compound 2u was obtained in a manner similar to Example 1.
[0355] <Example 53> Preparation of 3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-N-(pyrimidine-4-yl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide
[0356] Compound 2v was obtained in a manner similar to Example 1.
[0357] <Example 54> Preparation of Ethyl 3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-6-nitromidazo[1,2-a]pyridine-2-carboxylate
[0358] Compound 2w was obtained in a manner similar to Example 1.
[0359] <Example 55> Preparation of 3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-6-nitromidazo[1,2-a]pyridine-2-carboxylic acid
[0360] Compound 2W (0.13 mmol, 1 equivalent) prepared in Example 54 was dissolved in a THF:MeOH:H2O (8:1:1) solution, lithium hydroxide (0.55 mmol, 4 equivalents) was added, and the reaction mixture was stirred for 24 hours. After the reaction was completed, the mixed solution was concentrated under vacuum to remove the organic solvent. The mixed solution was acidified with 1M HCl to reach pH=5, and then the solvent was evaporated to obtain compound 2x.
[0361] <Example 56> Preparation of Ethyl 6-amino-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-a]pyridine-2-carboxylate
[0362]
[0363] SnCl2 (0.08 mmol, 1.5 equivalents) was added to a stirred solution of compound 2W (0.05 mmol, 1 equivalent) prepared in Example 54 dissolved in ethanol, and the mixture was refluxed for 16 hours. The solvent was removed under reduced pressure, and the reaction was quenched by adding a saturated solution of NaHCO3 and extracted with ethyl acetate to obtain compound 2y.
[0364] <Example 57> Preparation of 5-((2-chloro-6-(1H-pyrazole-4-yl)imidazo[1,2-a]pyridine-3-yl)ethynyl)-N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-fluoro-4-methylbenzamide
[0365] Compound 2z was obtained in a manner similar to Example 1.
[0366] <Example 58> Preparation of 3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-N-(2-(4-methylpiperazine-1-yl)ethyl)-6-nitromidazo[1,2-a]pyridine-2-carboxamide
[0367] Compound 2aa was obtained in a manner similar to Example 1.
[0369] The structural formulas of the compounds prepared in Examples 1-58 are summarized in Table 1 below.
[0370] Example Structure Yield; NMR(or LRMS) 1(1a) Yield 46%; 1 H NMR (600 MHz, CDCl3) δ 8.56 (s, 1H), 8.27 (s, 1H), 8.10 (d, J = 1.5 Hz, 1H), 7.97 (d, J = 9.5 Hz, 1H), 7.89 - 7.84 (m, 3H), 7.43 (d, J = 8.0 Hz, 1H), 7.37 (s, 1H), 7.22 (t, J = 7.2 Hz, 1H), 7.10 (s, 1H), 4.52 (q, J = 7.1 Hz, 2H), 2.70 (s, 3H), 2.29 (s, 3H), 1.47 (t, J = 7.1 Hz, 3H). 2(1b) Yield 39; 1 H NMR (600 MHz, DMSO-d6) δ 10.82 (s, 1H), 8.40 (d, J = 9.6 Hz, 1H), 8.13 (s, 1H) 8.01 (s, 1H), 7.90 (d, J = 7.2 Hz, 1H), 7.84 (s, 1H), 7.64 (d, J = 9.6 Hz, 1H), 7.50 (d, J = 10.8 Hz, 1H), 7.45 (t, J = 1.8 Hz, 1H), 7.44 (s, 1H), 4.40 (q, J = 7.1 Hz, 2H), 2.66 (s, 3H), 2.18 (s, 3H), 1.75 (s, 6H), 1.35 (t, J = 7.1 Hz, 3H). 3(1c) Yield 50%; 1 H NMR (600 MHz, Acetone-d6) δ 8.43 (s, 1H), 8.09 (s, 1H), 8.01 (d, J = 8.0, 1.8 Hz, 1H), 7.72 (d, J = 9.7 Hz, 1H), 7.66 (s, 1H), 7.53 - 7.50 (m, 2H), 7.40 (s, 1H), 7.33 - 7.30 (m, 1H), 7.21 - 7.17 (m, 1H), 7.08 - 7.05 (m, 1H), 6.94 (d, J = 9.7 Hz, 1H), 4.42 (q, J = 7.1 Hz, 2H), 2.73 (s, 3H), 2.22 (s, 3H), 1.42 (t, J = 7.1 Hz, 3H), 0.79 - 0.78 (m, 1H) 0.63 - 0.60 (m, 2H), 0.40 - 0.38 (m, 2H). 4(1d) Yield 48%; 1 H NMR (600 MHz, DMSO-d6) δ 10.81 (s, 1H), 8.30 (s, 1H), 8.21 (s, 1H), 8.15 (d, J = 7.3 Hz, 2H), 7.97 (d, J = 8.1 Hz, 1H), 7.82 (d, J = 9.8 Hz, 1H), 7.75 (s, 1H), 7.63 - 7.56 (m, 2H), 7.49 (s, 1H), 6.93 (d, J = 9.8 Hz, 1H), 4.35 (q, J = 7.1 Hz, 2H), 3.22 - 3.16 (m, 2H), 2.68 (s, 3H), 2.18 (s, 3H), 1.36 (t, J = 7.1 Hz, 3H), 0.88 - 0.81 (m, 1H), 0.52 - 0.45 (m, 2H), 0.28 (q, J = 4.7 Hz, 2H). 5(1e) Yield 28%; 1 H NMR (600 MHz, DMSO-d6) δ 10.84 (s, 1H), 8.32 (s, 1H), 8.24 - 8.18 (m, 2H), 8.01 (d, J = 7.9 Hz, 1H), 7.75 (s, 1H), 7.59 (d, J = 8.2 Hz, 1H), 7.50 (s, 1H), 7.22 (s, 1H), 6.89 (s, 2H), 6.67 (s, 1H), 4.35 (q, 7.1 Hz, 2H), 2.66 (s, 3H), 2.55 (s, 3H), 2.19 (s, 3H), 1.33 (t, J = 7.1 Hz, 3H). 6(1f) Yield 21%; 1 H NMR (600 MHz, Acetone-d6 δ 9.82 (s, 1H), 8.18 (s, 1H), 8.01 (d, J = 9.6 Hz, 1H), 7.99 (s, H), 7.93 (s, 1H), 7.49 (s, 1H), 7.34 (d, J = 11.5 Hz, 1H), 7.03 (d, J = 9.6 Hz, 1H), 4.62 (t, J = 6.0 Hz, 2H), 4.08 - 4.03 (m, 4H), 3.58 (t, J = 4.8 Hz, 2H), 2.69 (s, 3H), 2.54 (s, 6H), 2.21 (s, 3H), 1.96 (s, 6H), 1.20 (d, J = 7.1 Hz, 3H). 7(1g) Yield 37.93%; 1 H NMR (600 MHz, DMSO-d6) δ 10.56 (s, 1H), 8.27 (s, 2H), 8.09 (s, 1H), 8.02 (s, 1H), 7.91 (d, J = 6.6 Hz, 1H), 7.76 (d, J = 9.6 Hz, 1H), 7.40 (d, J = 11.2 Hz, 2H), 7.30 (s, 1H), 6.90 (d, J = 9.6 Hz, 1H), 6.76 (s, 1H), 4.32 (q, J = 7.1 Hz, 2H), 3.44 (s, 4H), 3.39 - 3.37 (m, 4H), 2.55 (s, 3H), 2.42 - 2.33 (m, 8H), 2.18 (s, 3H), 1.75 (s, 6H), 1.54 (s, 6H), 1.39 (s, 6H), 1.34 (t, J = 7.1 Hz, 3H). 8(1h) Yield 38%; 1 H NMR (600 MHz, DMSO-d6) δ 10.53 (s, 1H), 8.52 (s, 1H), 8.14 (d, J = 1.2 Hz, 1H), 7.94 (d, J = 9.6 Hz, 1H), 7.91 (s, 1H), 7.88 (s, 1H), 7.85 (s, 1H), 7.45 (d, J = 1.8 Hz, 2H), 7.28 (s, 1H), 6.98 (d, J = 9.6 Hz, 1H), 4.51 (t, J = 5.4 Hz, 2H), 4.35 (t, J = 5.4 Hz, 2H), 3.56 - 3.52 (m, 8H), 2.82 (t, J = 5.4 Hz, 2H), 2.76 (t, J = 6 Hz, 2H), 2.64 (s, 3H), 2.47 (s, 4H), 2.43 (s, 4H), 2.18 (s, 3H), 1.76 (s, 6H), 1.63 (s, 3H). 9(1i) Yield 41%; 1 H NMR (600 MHz, CDCl3) δ 8.51 (s, 1H), 8.06 (d, J = 1.8 Hz, 1H), 7.96 - 7.94 (m, 3H), 7.85 - 7.83 (m, 1H), 7.76 (d, J = 9 Hz, 1H), 7.36 (d, J = 7.8 Hz, 1H), 7.21 (d, J = 9 Hz, 1H), 4.52 (q, J = 7.2 Hz, 2H), 3.63 (s, 2H), 2.65 (s, 3H), 2.51 (s, 8H), 2.30 (s, 3H), 1.46 (t, J = 7.2 Hz, 3H). 10(1j) Yield 54%; 1 H NMR (600 MHz, CDCl3) δ 9.24 (d, J = 17.9 Hz, 1H), 8.04 - 7.96 (m, 3H), 7.82 (d, J = 9.4 Hz, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.31 - 7.20 (m, 3H), 7.17 (d, J = 9.4 Hz, 1H), 4.35 - 4.30 (m, 1H), 3.60 (s, 2H), 2.55 (s, 3H), 2.55 (s, 3H), 2.47 (s, 8H), 2.30 (s, 3H), 1.32 - 1.30 (m, 6H). 11(1k) Yield 57%; 1 H NMR (600 MHz, CDCl3) δ 9.10 (s, H), 8.05 (d, J = 13.8 Hz, 2H), 7.99 (d, J = 7.3 Hz, 1H), 7.86 (d, J = 7.3 Hz, 1H), 7.71 (d, J = 8.4 Hz, 1H), 7.50 (s, 1H), 7.29 (d, J = 7.8 Hz, 1H), 3.62 (s, 2H), 2.93 (s, 1H), 2.61 (s, 3H), 2.51 (s, 8H), 2.30 (s, 3H), 0.87 (s, 2H), 0.73 (s, 2H). 12(1l) Yield 47%; 1 H NMR (400 MHz, CDCl3) δ 10.65 (s, 1H), 8.41 (d, J = 9.6 Hz, 1H), 8.28 - 8.17 (m, 2H), 8.07 (d, J = 8.4 Hz, 1H), 7.99 (d, J = 8.0 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.66 (d, J = 9.6 Hz, 1H), 7.57 (d, J = 8.0 Hz, 1H), 6.43 (s, 1H), 3.58 (s, 2H), 2.69 (s, 3H), 2.41 (s, 8H), 2.25 (s, 3H), 2.20 (s, 3H). 13(1m) Yield 40%; 1 H NMR (600 MHz, CDCl3) δ 9.13 (s, 1H), 8.58 (s, 1H), 8.05 (d, J = 1.8 Hz, 1H), 7.98 (d, J = 1.8 Hz, 1H), 7.94 (dd, J = 6.0, 2.4 Hz, 1H), 7.89 (d, J = 9.0 Hz, 1H), 7.84 (dd, J = 6.0, 1.8 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.68 - 7.65 (m, 2H), 7.32 (d, J = 8.1 Hz, 1H), 7.21 (d, J = 9.6 Hz, 1H), 6.90 - 6.88 (m, 2H), 3.80 (s, 3H), 3.63 (s, 2H), 2.65 (s, 3H), 2.52 (s, 8H), 2.32 (s, 3H). 14(1n) Yield 54%; 1 H NMR (400 MHz, CDCl3) δ 10.28 (s, 1H), 8.25 (s, 1H), 8.09 (s, 1H), 7.99 (d, J = 8.8 Hz, 1H), 7.96 - 7.91 (m, 2H), 7.87 - 7.82 (m, 1H), 7.78 (d, J = 8.8 Hz, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.24 (s, 1H), 3.64 (s, 2H), 2.69 (s, 3H), 2.53 (s, 8H), 2.32 (s, 3H). 15(1o) Yield 31%; 1 H NMR (600 MHz, DMSO- d 6 ) δ 10.63 (s, 1H), 10.61 (s, 1H), 8.22 (s, 1H), 8.15 (s, 1H), 8.09 (s, 1H), 8.06 (d, J = 7.8 Hz, 1H), 7.93 (d, J = 7.8 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.54 - 7.51 (m, 1H), 6.80 (d, J = 10.8 Hz, 1H), 6.69 (d, J = 9.6 Hz, 1H), 3.63 (t, J = 5.4 Hz, 2H), 3.57 (s, 2H), 2.94 (t, J = 5.4 Hz, 2H), 2.63 (s, 3H), 2.54 (s, 1H), 2.39 (s, 8H), 2.19 (s, 3H), 1.20 (d, J = 6.5 Hz, 6H). 16(1p) Yield 27%; 1 H NMR (600 MHz, CDCl3) δ 8.10 (s, 2H), 7.90 (s, 1H), 7.73 (s, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.33 (d, J = 8.4 Hz, 1H), 7.21 (d, J = 7.8 Hz, 1H), 6.99 - 6.95 (m, 1H), 4.34 - 4.29 (m, 1H), 3.64 (s, 2H), 3.16 (s, 2H), 2.61 (s, 11H), 2.39 (s, 3H), 2.27 - 2.25 (m, 1H), 2.23 - 2.21 (m, 2H), 1.30 (d, J = 6.4 Hz, 12H). 17(1q) Yield 62.87%; 1 H NMR (600 MHz, CDCl3) δ 8.68 (d, J = 15.6 Hz, 1H), 8.34 (d, J = 7.8 Hz, 1H), 8.02 (s, 1H), 7.95 - 7.94 (m, 2H), 7.84 (s, 1H), 7.60 (s, 1H), 7.25 (s, 1H), 7.15 - 7.13 (m, 2H), 7.07 (s, 1H), 2.65 (s, 3H), 2.30 (s, 3H), 1.79 (s, 6H). 18(1r) Yield 20%; 1 H NMR (600 MHz, CDCl3) δ 8.59 (s, 1H), 8.04 (s, 1H), 7.99 (s, 1H), 7.95 (s, 1H), 7.86 - 7.77 (m, 3H), 7.62 (s, 1H), 7.20 (s, 1H), 7.09 - 7.06 (m, 2H), 6.62 (s, 1H), 3.38 (s, 2H), 2.68 (s, 2H), 2.57 (s, 2H), 2.51 (s, 3H), 2.29 (s, 3H), 1.77 (s, 6H), 1.66 (s, 6H), 1.48 (s, 2H). 19(1s) Yield 29%; 1 H NMR (600 MHz, CDCl3) δ 8.00 - 7.98 (m, 2H), 7.95 (t, J = 1.7 Hz, 1H), 7.85 - 7.81 (m, 2H), 7.77 (s, 1H), 7.64 (d, J = 6.6 Hz, 1H), 7.19 (d, J = 1.8 Hz, 1H), 7.08 - 7.05 (m, 2H), 6.59 (d, J = 4.2 Hz, 1H), 3.30 (d, J = 4.4 Hz, 2H), 2.76 (t, J = 6.5 Hz, 2H), 2.64 - 2.61 (m, 4H), 2.51 (d, J = 5.0 Hz, 3H), 2.29 (d, J = 2.0 Hz, 3H), 1.76 (d, J = 2.6 Hz, 6H), 1.08 (t, J = 7.0 Hz, 6H). 20(1t) Yield 21%; 1 H NMR (600 MHz, CDCl3) δ 8.78 (s, 1H), 7.97 (s, 1H), 7.93 (s, 1H), 7.88 (d, J = 9.6 Hz, 1H), 7.82 (d, J = 10.8 Hz, 2H), 7.62 (s, 1H), 7.18 (s, 1H), 7.10 (d, J = 9.0 Hz, 1H), 7.05 (s, 1H), 6.61 (s, 1H), 3.63 (s, 2H), 3.41 - 3.35 (m, 2H), 2.98 (s, 2H), 2.81 - 2.78 (t, J = 7.2 Hz, 2H), 2.52 (s, 3H), 2.29 (s, 3H), 1.90 (s, 16H), 1.76 (s, 6H). 21(1u) Yield 55%; 1 H NMR (600 MHz, CDCl3) δ 8.63 (d, J = 15.6 Hz, 1H), 8.33 (d, J = 7.8 Hz, 1H), 7.95 (t, J = 1.8 Hz, 1H), 7.87 (s, 1H), 7.84 (s, 1H), 7.82 (d, J = 1.8 Hz, 1H), 7.59 (t, J = 1.8 Hz, 1H), 7.25 (t, J = 1.8 Hz, 1H), 7.14 (d, J = 12.6 Hz, 1H), 7.08 (s, 1H), 6.84 (d, J = 9.6 Hz, 1H), 4.59 (t, J = 5.4 Hz, 2H), 2.70 (t, J = 5.4 Hz, 2H), 2.66 (s, 3H), 2.31 (s, 3H), 1.84 - 1.83 (m, 4H), 1.80 (s, 6H). 22(1v) Yield, 62%; 1 H NMR (600 MHz, CDCl3) δ 8.30 (d, J = 7.8 Hz, 1H), 7.96 (s, 1H), 7.87 (s, 1H), 7.82 (d, J = 9.6 Hz, 2H), 7.62 (s, 1H), 7.24 (t, J = 1.8 Hz, 1H), 7.13 (d, J = 12.6 Hz, 1H), 7.08 (s, 1H), 6.79 (d, J = 9.6 Hz, 1H), 4.57 (t, J = 5.2 Hz, 2H), 3.11 (t, J = 5.2 Hz, 2H), 2.97 - 2.93 (m, 1H), 2.64 (s, 3H), 2.31 (s, 3H), 1.79 (s, 6H), 1.13 (d, J = 6.3 Hz, 6H). 23(1w) 1 H NMR (600 MHz, DMSO- d 6 ) δ 10.77 (s, 1H), 8.14 (s, 1H), 8.11 (d, J = 9.6 Hz, 1H), 8.01 (d, J = 7.7 Hz, 2H), 7.87 (d, J = 7.2 Hz, 1H), 7.84 (s, 1H), 7.47 (d, J = 10.8 Hz, 1H), 7.44 (t, J = 1.2 Hz, 1H), 7.03 (d, J = 9.6 Hz, 1H), 4.51 (t, J = 5.6 Hz, 2H), 3.54 - 3.52 (m, 4H), 2.78 (s, 2H), 2.62 (s, 3H), 2.48 (s, 4H), 2.17 (s, 3H), 1.75 (s, 6H). 24(1x) Yield 20%; 1 H NMR (600 MHz, CDCl3) δ 8.41 (s, 1H), 8.04 (s, 1H), 8.00 (s, 1H), 7.93- 7.88 (m, 3H), 7.82 (d, J = 7.8 Hz, 1H), 7.76 (d, J = 7.8 Hz, 1H), 7.37 (d, J = 7.8 Hz, 1H), 7.13 (d, J = 9.0 Hz, 1H), 3.63 (s, 2H), 2.61 (s, 3H), 2.54 (s, 8H), 2.32 (s, 3H). 25(1y) Yield 64%; 1 H NMR (600 MHz, DMSO- d 6 ) δ 8.21 - 8.16 (m, 2H), 8.05 (d, J = 9.6 Hz, 1H), 8.0 - 7.97 (m, 2H), 7.90 - 7.85 (m, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.50 (d, J = 8.4 Hz, 1H), 7.01 - 6.99 (m, 1H), 4.46 (t, J = 5.4 Hz, 2H), 3.52 (s, 2H), 2.60 (s, 3H), 2.57 (t, J = 5.4 Hz, 2H), 2.35 (s, 8H), 2.10 (s, 3H), 1.59 (d, J = 2.4 Hz, 2H), 1.26 - 1.25 (m, 2H). 26(1z) Yield 53.71%; 1 H NMR (600 MHz, DMSO- d 6 ) δ 10.58 (s, 1H), 8.22 (d, J = 16.8 Hz, 2H), 8.14 (d, J = 9.6 Hz, 1H), 8.07 (d, J = 7.8 Hz, 1H), 8.04 (s, 1H), 7.95 (d, J = 7.8 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.04 (d, J = 9.6 Hz, 1H), 4.50 (s, 2H), 3.56 (s, 2H), 3.10 (s, 2H), 2.95 (s, 1H), 2.64 (s, 3H), 2.39 (s, 8H), 2.16 (s, 3H), 2.00 - 1.91 (m, 1H) 1.06 (d, J = 5.5 Hz, 6H). 27(1aa) Yield, 59%. 1 H NMR (600 MHz, DMSO- d 6 ) δ 10.55 (s, 1H), 8.22 (s, 1H), 8.19 (s, 1H), 8.11 (d, J = 9.6 Hz, 1H), 8.07 (d, J = 8.4 Hz, 1H), 8.03 (s, 1H), 7.93 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H), 7.04 (d, J = 9.6 Hz, 1H), 4.51 (t, J = 5.7 Hz, 2H), 3.56 (s, 2H), 3.53 - 3.52 (m, 4H), 2.76 (t, J = 5.7 Hz, 2H), 2.63 (s, 4H), 2.46 (s, 3H), 2.38 (s, 8H), 2.18 (s, 3H). 28(1ab) Yield 43%; 1 H NMR (400 MHz, DMSO- d 6 ) δ 10.60 (s, 1H), 9.46 (s, 1H), 8.23 - 8.22 (m, 2H), 8.04 (dd, J = 6.8, 1.6 Hz, 1H), 7.97 - 7.91 (m, 3H), 7.83 (d, J = 9.2 Hz, 2H), 7.71 (d, J = 8.8 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 6.99 (d, J = 10 Hz, 1H), 6.92 (d, J = 9.2 Hz, 2H), 3.65 (s, 3H), 3.58 (s, 2H), 2.63 (s, 3H), 2.41 (s, 8H), 2.20 (s, 3H). 29(1ac) Yield 69%; 1 H NMR (400 MHz, DMSO- d 6 ) δ 10.55 (s, 1H), 8.23 (d, J = 2.0 Hz, 1H), 8.18 (d, J = 1.6 Hz, 1H), 8.09 - 8.06 (m, 1H), 7.98 (d, J = 10 Hz, 1H), 7.92 (s, 1H), 7.91 (d, J = 1.6 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.31 (d, J = 10.0 Hz, 1H), 3.76 - 3.74 (m, 4H), 3.56 - 3.53 (m, 6H), 2.61 (s, 3H), 2.39 (s, 8H), 2.17 (s, 3H). 30(1ad) Yield 45%; LRMS (ESI + ) m / z : 659.47 [M+H] + (calculated for C 34 H 33 F3N8O3, 659.27). 31(1ae) Yield 40%; 1 H NMR (400 MHz, CDCl3) δ 9.22 (s, 1H), 9.17 (s, 1H), 8.03 (s, 2H), 7.97 (s, 2H), 7.80 (t, J = 8.5 Hz, 2H), 7.69 (d, J = 8.5 Hz, 1H), 7.55 (s, 1H), 7.23 (d, J = 8.0 Hz, 1H), 7.17 (d, J = 9.5 Hz, 1H), 3.84 (s, 3H), 3.61 (s, 2H), 2.53- 2.50 (m, 11H), 2.32 (s, 3H). 32(1af) Yield 40%; 1 H NMR (400 MHz, CDCl3) δ 9.17 (s, 1H), 8.01 (s, 2H), 7.95 (s, 1H), 7.83 (d, J = 9.4 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.71 (d, J = 8.1 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 7.17 (d, J = 9.3 Hz, 1H), 3.96 - 3.77 (m, 4H), 3.62 (s, 2H), 2.58 - 2.42 (m, 15H), 2.33 (s, 3H), 2.30 (s, 3H). 33(1ag) 1 H NMR (400 MHz, DMSO- d 6 ) δ 10.69 (s, 1H), 10.65 (s, 1H), 10.49 (s, 1H), 8.22 - 8.20 (m, 2H), 7.80 (s, 1H), 7.57 (d, J = 8.1 Hz, 1H), 7.30 (d, J = 8.3 Hz, 1H), 7.24 (d, J = 0.6 Hz, 1H), 7.19 (d, J = 3.5 Hz, 1H), 7.17 (d, J = 3.5 Hz, 1H), 6.93 (s, 1H), 5.35 - 5.29 (m, 2H), 4.49 - 4.46 (m, 2H), 3.83 (s, 3H), 3.51 (s, 2H), 2.70 (s, 3H), 2.17 - 2.14 (m, 11H), 2.04 - 2.02 (s, 1H), 0.99 (s, 3H), 0.97 (s, 3H). 34(1ah) 1 H NMR (400 MHz, DMSO- d 6 ) δ 10.66 (s, 1H), 8.23 (d, J = 2.0 Hz, 1H), 8.18 (d, J = 9.7 Hz, 1H), 8.14 (d, J = 2.0 Hz, 1H), 8.06 (dd, J = 8.0, 1.8 Hz, 1H), 7.97 (dd, J = 8.0, 1.8 Hz, 1H), 7.71 (d, J = 8.6 Hz, 1H), 7.56 (d, J = 8.2 Hz, 1H), 7.12 (d, J = 9.7 Hz, 1H), 5.32 (t, J = 4.3 Hz, 2H), 4.53 (s, 2H), 3.76 - 3.69 (m, 4H), 3.57 (s, 2H), 2.64 (s, 3H), 2.40 - 2.33 (m, 12H), 2.19 (s, 3H), 2.17 (s, 3H), 2.03 - 2.01 (m, 1H), 1.07 (d, J = 6.2 Hz, 6H). 35(2a) Yield 30%; 1 H NMR (600 MHz, DMSO- d 6) δ 10.76 (s, 1H), 8.88 - 8.82 (m, 1H), 8.34 (s, 1H), 8.29 (s, 1H), 8.21 (s, 1H), 8.15 (s, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.76 (s, 1H), 7.74 (s, 1H), 7.62 - 7.56 (m, 2H), 7.49 (s, 1H), 2.61 (s, 3H), 2.17 (s, 3H). 36(2b) Yield 32%; 1 H NMR (600 MHz, DMSO) δ 10.84 (s, 1H), 8.94 - 8.91 (m, 1H), 8.21 - 8.15 (m, 2H), 8.02 (s, 1H), 7.86 (s, 1H), 7.75 (dd, J = 8.4, 0.6 Hz, 1H), 7.59 (dd, J = 7.2, 1.8 Hz, 1H), 7.48 - 7.45 (m, 2H), 7.20 (s, 1H), 2.60 (s, 3H), 2.19 (s, 3H), 1.75 (s, 6H). 37(2c) Yield 42%; 1 H NMR (600 MHz, DMSO- d 6) δ 10.80 (s, 1H), 9.02 (d, J = 1.8 Hz, 1H), 8.89 (dd, J = 1.2, 0.6 Hz, 1H), 8.63 (dd, J = 3.6, 1.2 Hz, 1H), 8.22 - 8.20 (m, 1H), 8.11 (s, 1H), 8.10 (s, 1H), 7.99 (s, 1H), 7.90 (dd, J = 7.8, 1.8 Hz, 1H), 7.86 - 7.81 (m, 2H), 7.54 - 7.52 (m, 1H), 7.47 - 7.40 (m, 3H), 2.61 (s, 3H), 2.17 (s, 3H), 1.74 (s, 6H). 38(2d) Yield 51%; 1 H NMR (600 MHz, CDCl3) δ 9.07 (s, 1H), 8.88 (s, 1H), 8.69 (d, J = 4.8 Hz, 1H), 8.40 (s, 1H), 8.27 (s, 1H), 8.00 (s, 1H), 7.93 - 7.90 (m, 2H), 7.84 (d, J = 7.8 Hz, 1H), 7.73 (d, J = 9.0 1H), 7.62 - 7.57(m, 1H), 7.50 (d, J = 9.0 Hz, 1H), 7.45 - 7.44 (m, 1H), 7.39 - 7.36 (m, 2H), 7.08 (s, 1H), 2.57 (s, 3H), 2.28 (s, 3H). 39(2e) Yield 26%; 1 H NMR (600 MHz, DMSO- d 6) δ 10.76 (s, 1H), 8.79 (s, 1H), 8.34 (s, 1H), 8.30 (s, 1H), 8.22 (s, 1H), 8.17 (s, 1H), 8.13 (s, 1H), 7.98 - 7.94(m, 2H), 7.78 - 7.73 (m, 4H), 7.59 (d, J = 7.8 Hz, 1H), 7.50 (s, 1H), 2.65 (s, 3H), 2.18 (s, 3H). 40(2f) Yield 51%; 1 H NMR (600 MHz, DMSO- d 6) δ 10.75 (s, 1H), 8.68 (s, 1H), 8.29 (s, 2H), 8.21 (s, 1H), 8.15 (s, 1H), 7.96 (d, J = 7.6 Hz, 1H), 7.84 (d, J = 9.3, 1.5 Hz, 1H), 7.78 - 7.72 (m, 2H), 7.70 (d, J = 2.9 Hz, 1H), 7.65 (d, J = 4.9 Hz, 1H), 7.58 (d, J = 8.8 Hz, 1H), 7.48 (s, 1H), 7.20 - 7.18 (m, 1H), 2.65 (s, 3H), 2.17 (s, 3H). 41(2g) Yield 24%; 1 H NMR (600 MHz, DMSO- d 6) δ 10.81 (s, 1H), 8.85 (s, 1H), 8.31 (s, 1H), 8.21 (s, 1H), 8.18 (s, 1H), 7.99 (d, J = 7.9 Hz, 1H), 7.79 - 7.73 (m, 2H), 7.60 (d, J = 8.1 Hz, 1H), 7.49 (s, 1H), 7.39 (d, J = 7.9 Hz, 1H), 7.32 - 7.28 (m, 1H), 7.17 (d, J = 7.4 Hz, 1H), 7.08 - 7.04 (m, 1H), 6.95 (s, 1H), 2.65 (s, 3H), 2.18 (s, 3H). 42(2h) Yield 47.54; 1 H NMR (600 MHz, Acetone) δ 8.65 (s, 1H), 7.98 - 7.93 (m, 1H), 7.87 (s, 1H), 7.71 - 7.67 (m, 3H), 7.63 - 7.60 (m, 1H), 7.56 - 7.54 (m, 2H), 7.50 (d, J = 8.4 Hz, 1H), 7.41 (d, J = 7.2 Hz, 1H), 7.36 (d, J = 7.8 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 7.30 (d, J = 5.1 Hz, 1H), 7.28 (d, J = 7.8 Hz, 1H), 7.20 - 7.17(m, 1H), 7.07 - 7.04 (m, 1H), 6.98 - 6.95 (m, 1H), 2.64 (s, 3H), 2.42 (s, 3H). 43(2i) Yield 32%; 1 H NMR (600 MHz, CDCl3) δ 9.66 (s, 1H), 9.21 (s, 1H), 9.08 (s, 2H), 8.63 (s, 1H), 8.45 (s, 1H), 8.23 (s, 1H), 8.10 (d, J = 8.4 Hz, 1H), 8.00 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 9.2 Hz, 1H), 7.51 (d, J = 9.2 Hz, 1H), 7.35 (d, J = 8.0 Hz, 1H), 3.67 (s, 2H), 3.62 (s, 3H), 2.80 (s, 4H), 2.68 (s, 4H), 2.58 (s, 3H). 44(2j) Yield 27%; 1 H NMR (600 MHz, CDCl3) δ 8.65 (s, 1H), 8.04 - 7.95 (m, 3H), 7.95 (s, 1H), 7.79 - 7.96 (m, 2H), 7.35 - 7.31 (m, 2H), 6.98 (d, J = 9.2 Hz, 1H), 3.65 (s, 2H), 2.57 (s, 11H), 2.34 (s, 3H), 2.02 - 1.96 (m, 1H), 1.06 - 1.03 (m, 2H), 0.75 - 0.72 (m, 2H). 45(2k) Yield, 32%; 1 H NMR (600 MHz, CDCl3) δ 8.82 (s, 1H), 8.34 (s, 1H), 8.13 (s, 1H), 8.01 (d, J = 7.6 Hz, 2H), 7.84 (d, J = 7.2 Hz, 1H), 7.82 (s, 1H), 7.68 (d, J = 7.2 Hz, 1H), 7.53 (d, J = 8.1 Hz, 2H), 7.43 (d, J = 7.6 Hz, 1H), 7.36 (d, J = 6.6 Hz, 1H), 6.74 (s, 1H), 3.53 (s, 2H), 2.64 - 2.57 (m, 11H), 2.46 (s, 3H). 46(2l) Yield 18%; 1 H NMR (600 MHz, CDCl3) δ 8.36 (s, 1H), 8.25 (s, 1H), 8.12 (s, 1H), 7.96 - 7.94 (m, 2H), 7.82 (d, J = 7.8 Hz, 1H), 7.78 (s, 1H), 7.75 (d, J = 7.8 Hz, 1H), 7.64 (d, J = 9.4 Hz, 1H), 7.53 (d, J = 10.8 Hz, 2H), 7.43 (d, J = 8.6 Hz, 2H), 7.18 (s, 1H), 6.70 (s, 1H), 3.38 (s, 2H), 2.67 - 2.47 (m, 11H), 2.38 (s, 3H). 47(2m) Yield 30%. 1 H NMR (600 MHz, CDCl3) δ 8.45 (s, 1H), 8.31 (s, 1H), 8.02 - 7.93 (m, 3H), 7.80 (d, J = 7.8 Hz, 1H), 7.74 (d, J = 7.8 Hz, 1H), 7.53 (d, J = 9.0 Hz, 1H), 7.47 (d, J = 9.0 Hz, 1H), 7.37 (d, J = 7.8 Hz, 1H), 7.05 (s, 2H), 6.92 (d, J = 7.6 Hz, 1H), 6.03 (s, 2H), 3.66 (s, 2H), 2.59 (s, 11H), 2.39 (s, 3H). 48(2q) Yield 23%; 1 H NMR (600 MHz, Acetone- d 6 ) δ 10.14 (s, 1H), 9.07 (s, 1H), 8.41 (s, 1H), 8.35 (s, 1H), 8.22 (s, 1H), 8.12 (s, 1H), 8.04 (d, J = 7.4 Hz, 1H), 7.92 (d, J = 9.5 Hz, 1H), 7.73 (d, J = 9.5 Hz, 1H), 7.68 (s, 1H), 7.56 (d, J = 7.4 Hz, 1H), 7.42 (s, 1H), 3.99 (s, 3H), 2.72 (s, 3H), 2.22 (s, 3H). 49(2r) Yield 43%; 1 H NMR (600 MHz, DMSO- d 6 ) δ 10.60 (s, 1H), 9.02 (s, 1H), 8.25 (s, 1H), 8.21 (s, 1H), 8.05 (d, J = 7.8 Hz, 1H), 7.99 - 7.94 (m, 1H), 7.76 (d, J = 8.9 Hz, 1H), 7.71 (d, J = 8.2 Hz, 1H), 7.55 (d, J = 7.8 Hz, 1H), 3.78 (s, 2H), 3.69 (s, 2H), 3.60 - 3.46 (m, 4H), 3.27 - 3.26 (m, 2H), 2.60 (s, 3H), 2.42 - 2.35 (m,11H). 50(2s) Yield 17%; 1 H NMR (600 MHz, CDCl3) δ 9.27 (s, 1H), 8.96 (s, 1H), 8.63 (s, 1H), 8.05 (s, 2H), 8.0 (s, 1H) 7.98 (d, J = 9.0 Hz, 1H), 7.85 (d, J = 7.8 Hz, 1H), 7.701 - 7.69 (m, 2H), 7.58 (s, 1H), 7.50 (d, J = 9.0 Hz, 1H), 7.30 (d, J = 7.8 Hz, 1H), 3.87 (s, 3H), 3.62 (s, 2H), 2.57 (s, 11H), 2.34 (s, 3H). 51(2t) Yield 20%; 1 H NMR (600 MHz, CDCl3) δ 8.70 (s, 1H), 8.49 (s, 1H), 8.19 (s, 1H), 7.96 (s, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.74 (d, J = 8.8 Hz, 1H), 7.63 (d, J = 7.1 Hz, 1H), 7.48 - 7.46 (m, 1H), 7.39 (d, J = 7.7 Hz, 2H), 6.86 (s, 1H), 6.75 (s, 1H), 3.38 (s, 2H), 2.59 (s,11H), 2.49 (s, 3H), 2.45 (s, 3H). 52(2u) Yield 20%; 1 H NMR (600 MHz, DMSO- d 6 ) δ 10.64 (s, 1H), 9.32 (s, 1H), 9.07 (s, 1H), 8.63 (s, 1H), 8.33 (d, J = 1.8 Hz, 1H), 8.23 (d, J = 1.8 Hz, 1H), 8.07 (d, J = 8.4 Hz, 1H), 8.03 (d, J = 9.4 Hz, 1H), 7.99 (d, J = 7.9, 1.7 Hz, 1H), 7.87 (d, J = 9.4 Hz, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.72 (d, J = 8.2 Hz, 1H), 7.64 - 7.61 (m, 1H), 7.58 (d, J = 8.2 Hz, 1H), 3.58 (s, 2H), 2.69 (s, 3H), 2.44 (s, 11H). 53(2v) Yield 17%; 1 H NMR (600 MHz, Acetone- d 6) δ 10.04 (s, 1H), 9.14 (s, 1H), 8.92 (d, J = 1.0 Hz, 1H), 8.76 (d, J = 5.7 Hz, 1H), 8.39 (d, J = 1.8 Hz, 1H), 8.36 (d, J = 5.7, 1.2 Hz, 1H), 8.31 (d, J = 1.8 Hz, 1H), 8.11 (d, J = 8.2 Hz, 1H), 8.04 (d, J = 11.4, 5.3 Hz, 2H), 7.82 (d, J = 9.5, 1.7 Hz, 1H), 7.79 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 7.5 Hz, 1H), 7.36 - 7.32 (m, 1H), 3.65 (s, 2H), 2.76 (s, 3H), 2.53 (s, 8H), 2.29 (s, 3H). 54(2w) Yield 33%; 1 H NMR (600 MHz, CDCl3) δ 10.40 (s, 1H), 8.49 (s, 1H), 8.24 (d, J = 9.6 Hz, 1H), 8.02 (s, 1H), 7.94 - 7.92 (m, 2H), 7.87 (d, J = 7.8 Hz, 1H), 7.79 (d, J = 10.2 Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.38 (d, J = 7.8 Hz, 1H), 4.59 - 4.52 (m, 2H), 3.63 (s, 2H), 2.61 (s, 3H), 2.50 (s, 8H), 2.31 (s, 3H), 1.48 (t, J = 6.4 Hz, 3H). 55(2x) Yield 42%; 1H NMR (600 MHz, DMSO) δ 10.86 (s, 1H), 9.51 (dd, J = 2.2, 0.7 Hz, H), 8.34 (s, 1H), 8.30 (s, 1H), 8.21 (d, J = 5.6 Hz, 1H), 8.18 (d, J = 9.9, 1H), 8.15 (d, J = 8.7 Hz, 1H), 8.08 (d, J = 8.2 Hz, 1H), 7.96 (d, J = 9.9 Hz, 1H), 7.76 (s, 1H), 7.57 (d, J = 8.2 Hz, 1H), 3.15 (s, 2H), 3.05 (s, 4H), 2.89 (s, 4H), 2.71 (s, 3H), 2.66 (s, 3H). 56(2y) Yield 19%; 1 H NMR (600 MHz, CDCl3) δ 8.84 (s, 1H), 8.61 (s, 1H), 8.01 - 7.98 (m, 2H), 7.93 (d, J = 7.3 Hz, 1H), 7.82 (s, 1H), 7.74 (d, J = 4.1 Hz, 1H), 7.53 (d, J = 8.6 Hz, 1H), 7.33 (d, J = 4.1 Hz, 1H), 7.11 - 7.04 (m, 1H), 4.88 (s, 2H), 4.46 (s, 2H), 3.63 (s, 2H), 2.57 (s, 11H), 2.33 (s, 3H), 1.42 (s, 3H). 57(2z) 1 H NMR (600 MHz, CDCl3) δ 10.26 (s, 1H), 8.38 (s, 1H), 7.94 (s, 1H), 7.81 (s, 1H), 7.56 (d, J = 10.2 Hz, 1H), 7.50 - 7.45 (m, 1H), 7.41 - 7.39 (m, 2H), 7.32 - 7.29 (m, 2H), 7.17 (s, 1H), 7.14 (s, 1H), 7.07 (s, 1H), 6.87 (s, 1H), 2.53 (s, 3H), 2.30 (s, 3H), 1.76 (s, 6H). 58(2aa) 1 H NMR (600 MHz, CDCl3) δ 9.36 (s, 1H), 8.85 (s, 1H), 8.10 (s, 1H), 8.01 (s, 1H), 7.98 (d, J = 8.0 Hz, 1H), 7.92 - 7.98 (m, 1H), 7.86 (d, J = 7.6 Hz, 1H), 7.81 (s, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.69 (d, J = 9.6 Hz, 1H), 7.32 (d, J = 7.6 Hz, 1H), 3.64 (s, 2H), 3.60 (s, 4H), 2.67 - 2.50 (m, 16H), 2.44 (s, 3H), 2.36 (s, 3H), 2.34 (s, 3H).
[0372] <Experimental Example 1> Evaluation of Rearrangement (RET) Kinase Inhibitory Activity During Transfection
[0373] To confirm the enzyme inhibitory activity of the compound represented by Formula 1 according to the present invention against RET kinase, the following experiment was performed. The results are shown in Tables 2 to 6 below.
[0374] 1) Experimental Method
[0375] The inhibitory activity of the compounds of the embodiment of the present invention was investigated against a RET mutant (RETWT, RETG810R, RETV804M, RETV804M-KIF5B, RET-KIF5B, RET-CCDC6, RET-NCOA4) kinase panel (Reaction Biology Corp). Using radiolabeled ATP ([γ-33P] ATP), the degree to which the substrate was replaced by a 33P-phosphorylated substrate was measured, and the change in kinase activity was measured from the measurement of the radiolabeled phosphorylated substrate. The test was conducted by treating with 1 μM of the compounds of the embodiment against an ATP concentration of 10 μM. The residual activity (%) after inhibition of the compounds of the embodiment for each kinase panel is shown in Table 2 below. In addition, the results of the test conducted by treating with 0.1 μM of the compounds of the embodiment are shown in Table 3.
[0376] Examples Residual enzyme activity (%) (Calculated value compared to DMSO control group) RET(wt) G810R V804M RET-CCDC6 RET-NCOA4 RET-KIF5B RET (V804M)-KIF5B 2 99.65 ± 1.03 105.15 ± 5.42 120.23 ± 0.58 NT NT NT NT 3 98.18 ± 0.34 104.65 ± 0.30 98.93 ± 2.37 13.89 ± 0.07 21.1 ± 0.12 22.1 ± 0.05 NT 4 96.2 ± 0.31 100.86 ± 4.70 100.08 ± 3.23 NT NT NT NT 5 45.75 ± 5.61 56.85 ± 3.09 9.81 ± 2.52 38.01 ± 0.89 69.99 ± 2.22 NT NT 6 101.01 ± 4.39 110.06 ± 6.67 102.42 ± 0.93 NT NT NT NT 7 105.81 ± 2.94 98.99 ± 2.37 107.81 ± 0.30 NT NT NT NT 8 102.86 ± 4.67 114.61 ± 7.93 115.25 ± 4.28 NT NT NT NT 11 NT 92.90 ± 1.71 NT NT NT NT NT 12 NT 96.58 ± 2.98 NT NT NT NT NT 13 NT 107.06 ± 1.81 NT NT NT NT NT 14 NT 77.23 ± 1.32 NT NT NT NT NT 15 NT 92.23 ± 1.26 NT NT NT NT NT 16 NT 92.82 ± 2.52 NT NT NT NT NT 30 96.19 ± 5.45 100.51 ± 0.24 97.51 ± 0.61 87.14 ± 0.24 93.42 ± 0.34 94.29 ± 0.36 NT 31 NT 94.46 ± 0.91 NT NT NT NT NT 32 NT 100.11 ± 0.60 NT NT NT NT NT 33 NT 103.09 ± 2.69 NT NT NT NT NT 34 NT 103.42 ± 3.71 NT NT NT NT NT 35 65.69 ± 5.77 82.45 ± 2.19 86.91 ± 2.18 NT NT NT NT 36 104.65 ± 2.63 101.27 ± 0.79 96.45 ± 9.72 NT NT NT NT 37 51.74 ± 2.67 82.05 ± 2.50 48.61 ± 4.13 15.81 ± 0.16 41.54 ± 0.34 NT NT 39 82.85 ± 2.78 92.87 ± 1.82 82.3 ± 6.44 NT NT NT NT 40 79.23 ± 3.85 93.04 ± 4.99 67.19 ± 2.79 38.38 ± 0.11 67.12 ± 0.84 NT NT 41 105.91 ± 7.54 107.55 ± 7.16 97.21 ± 0.69 NT NT NT NT 42 106.01 ± 5.87 102.81 ± 4.20 100.58 ± 4.33 NT NT NT NT 43 67.67 ± 1.49 86.48 ± 4.78 4.75 ± 0.10 3.43 ± 0.19 21.27 ± 0.66 21.83 ± 0.73 NT 44 69.4 ± 3.58 87.88 ± 6.70 13.35 ± 1.09 8.11 ± 0.12 28.46 ± 1.11 30.92 ± 0.94 NT 45 55.87 ± 4.59 69.72 ± 3.50 6.99 ± 1.03 7.28 ± 0.24 29.31 ± 0.17 29.82 ± 0.82 NT 46 52.63 ± 2.28 70.03 ± 0.29 3.9 ± 0.11 5.55 ± 0.76 25.32 ± 1.10 NT NT 47 75.03 ± 4.84 81.45 ± 6.87 5.18 ± 0.15 8.74 ± 0.02 34.91 ± 0.07 NT NT 48 102.61 ± 3.62 111.29 ± 4.40 96.03 ± 1.28 NT NT NT NT 49 96.14 ± 2.86 101.58 ± 1.73 106.59 ± 3.03 68.73 ± 0.29 82.97 ± 1.58 87.39 ± 0.28 NT 50 106.46 ± 8.19 109.09 ± 9.28 105.59 ± 1.11 83.19 ± 7.27 92.57 ± 1.27 89.92 ± 0.30 NT 51 101.1 ± 3.58 106.47 ± 4.62 98.3 ± 2.63 71.53 ± 2.58 83.88 ± 0.30 92.89 ± 0.56 NT 52 93.03 ± 3.44 98.3 ± 4.30 104.65 ± 2.84 NT NT NT NT 53 87.26 ± 4.26 93.29 ± 3.30 88.34 ± 4.39 NT NT NT NT 54 40.91 ± 0.85 63.16 ± 2.28 20.61 ± 2.63 6.71 ± 0.61 27.11 ± 0.28 21.78 ± 1.82 NT 57 93.85 ± 1.20 101.15 ± 2.64 108.65 ± 4.29 89.77 ± 0.24 95.13 ± 0.84 95.13 ± 0.84 NT 58 88.07±0.55 104.96±3.64 88.33±2.69 NT NT NT NT
[0377] * NT: not tested
[0378] Examples Residual enzyme activity (%) (Calculated value compared to DMSO control group) RET(wt) G810R V804M RET-CCDC6 RET-NCOA4 RET-KIF5B RET (V804M)-KIF5B 9 NT 96 ± 1.33 NT NT NT NT NT 10 NT 102.21 ± 0.03 NT NT NT NT NT 17 NT 96.80 ± 0.71 52.19 ± 1.16 NT NT NT 97.13 ± 3.11 18 NT 99.15 ± 1.05 100.07 ± 1.01 NT NT NT 95.31 ± 6.27 19 NT 98.47 ± 0.09 97.81 ± 0.33 NT NT NT 106.20 ± 12.12 20 NT 100.74 ± 0.07 89.14 ± 0 NT NT NT 86.18 ± 1.11 21 NT 96.86 ± 2.70 36.02 ± 0.36 NT NT NT 89.41 ± 8.66 22 NT 91.85 ± 1.64 17.89 ± 1.09 NT NT NT 70.39 ± 2.46 23 30.67 ± 0.59 59.66 ± 0.74 3.14 ± 0.42 0.48 ± 0.26 4.12 ± 0.12 NT NT 24 NT 61.89 ± 2.33 2.78 ± 0.53 NT NT NT 71.76 ± 1.09 25 NT 84.79 ± 1.23 6.70 ± 0.04 NT NT NT 91.98 ± 0.74 26 NT 58.22 ± 0.22 0.75 ± 0.01 NT NT NT 36.95 ± 1.59 27 NT 56.85 ± 3.83 2.48 ± 0.13 NT NT NT 68.13 ± 0.56 28 NT 46.57 ± 1.97 NT NT NT NT NT 29 NT 26.39 ± 2.77 NT NT NT NT NT 38 NT 102.48 ± 0.37 93.54 ± 0.06 NT NT NT 88.92 ± 3.63 55 NT 103.52 ± 1.48 88.02 ± 0.33 NT NT NT 102.8 ± 5.28 56 NT 98.81 ± 0.37 29.42 ± 0.94 NT NT NT 109.97 ± 9.83
[0379] * NT: not tested
[0380] As a control compound, Staurosporine was tested in a 10-dose IC50 mode with 4-fold serial dilutions starting at 20 μM. The example compounds were tested in a 10-dose IC50 mode with 3-fold serial dilutions starting at 10 or 30 μM. Among the inhibitory activities of the example compounds in Tables 1 and 2 for each calculated kinase panel, examples showing significant results were selected, and the IC50, an indicator of inhibitory activity, was measured and is shown in Tables 3 to 5 below.
[0381] The Journal of Clinical Endocrinology & Metabolism, a non-patent literature According to , Volume 98, Issue 5, 1 May 2013, Pages E811-E819, the RET of Ponatinib V804M The IC50 for is known to be 33.9 nM.
[0382] Entry Enzyme assays IC 50 (nM) RET G810R RET V804M KIF5B-RET (V804M) Example 5 >2000 101.8 >2000 Example 24 19.8 < 0.5 281 Example 26 25.3 < 0.5 19.4 Example 27 11 < 0.5 84.5 Example 23 1301 7.4 622 Example 28 89.8 0.9 136.7 Example 29 41.3 0.1 47.8
[0383] Entry Enzyme assays IC 50 (nM) RET wt KIF5B-RET Example 5 921 >2000 Example 26 3.6 1.2 Example 23 345 43.7 Example 37 1800 NT
[0384] Entry Kinase assay IC 50 (nM) RET V804M Example 37 0.80 Example 44 NT Example 45 0.024 Example 43 0.017 Example 47 0.028 Example 54 0.044 Example 56 NT
[0385] Looking at Tables 2 to 6 above, it was confirmed that the compounds of the examples exhibited inhibitory activity against various RET mutations including RET kinase and RET mutations G810R, V804M, RET-CCDC6, RET-NCOA4, RET-KIF5B, and RET(V804M)-KIF5B.
[0386] Therefore, since the compounds of the above examples can excellently inhibit the activity of RET kinase, they can be usefully utilized in pharmaceutical compositions for the prevention or treatment of RET kinase-related diseases, such as cancer, containing them as active ingredients.
[0388] <Experimental Example 2> Evaluation of Ba / F3 Cell Proliferation Inhibition
[0389] To confirm the inhibitory effect of the compound represented by Formula 1 according to the present invention on RET mutant cell growth in Ba / F3 cell lines, the following experiment was performed. The results are shown in Tables 7 and 8 below.
[0390] The above “Ba / F3” is an artificial rodent cell model that stably demonstrates RET mutation overexpression, and as a result, cell activity does not necessarily correspond to RET enzyme activity.
[0391] 1) Experimental Method
[0392] Ba / F3 cell lines expressing each KIF5B-RET mutant gene (KIF5B-RET(Ba / F3), KIF5B-RET(V804M)(Ba / F3), KIF5B-RET(V804L)(Ba / F3), KIF5B-RET(G810R)(Ba / F3), KIF5B-RET(G810S)(Ba / F3), KIF5B-RET(G810C)(Ba / F3), KIF5B-RET(G810A)(Ba / F3), KIF5B-RET(M918T / V804M / G810S)(Ba / F3), KIF5B-RET(M918T / V804M / G810C)(Ba / F3)) were seeded into 96-well plates at a density of 1×104 / 90 μL / well, and After adding 10 μL / well of culture solution containing each example compound or DMSO control at nine concentrations (15.2 nM to 100 μM) serially diluted three-fold to achieve a final concentration of 0 to 10 μM, the temperature condition was 37 Incubated in a CO2 incubator for 72 hours. After 72 hours of incubation, the plates treated with the compound were removed, 10 μL / well of Cell Counting Kit-8 solution was added, and the mixture was thoroughly mixed. Subsequently, the temperature condition was 37 The cells were cultured in a CO2 incubator for 2 hours, and the absorbance at 450 nm was measured using a microplate reader. The data were expressed as a percentage relative to the vehicle-treated cells, and the GI 50 value was calculated using GraphPad Prism 8.0 (GraphPad software Inc., San Diego). The results are shown in Tables 7 and 8 below.
[0393] Examples Cell Viability (GI 50 uM) in Ba / F3 Cell-lines with Each KIF5B-RET Mutant Overexpresstion RET(wt) V804M V804L G810R G810S G810C G810A 1(1a) NT NT NT NT NT NT NT 2(1b) >10 NT >10 >10 >10 >10 >10 3(1c) 2.21 NT >3.89 >3.89 >3.89 3.15 >3.89 4(1d) >4.00 NT >4.00 >4.00 >4.00 >4.00 >4.00 5(1e) >10 NT >10 >10 >10 >10 >10 6(1f) >10 NT >10 >10 >10 >10 >10 7(1g) 0.99 NT 1.61 1.24 1.68 1.78 1.21 8(1h) >10 NT >10 >10 >10 >10 >10 23(1w) 0.11 1.63 1.84 0.44 0.10 0.60 0.05 30(1ad) 2.57 NT >5.84 3.38 4.83 >5.84 2.55 35(2a) 7.05 NT >10 >10 >10 >10 >10 36(2b) 8.144 NT >10 >10 >10 >10 2.947 37(2c) >10 >10 0.93 >10 >10 >10 0.89 39(2e) >10 NT >10 >10 >10 >10 >10 40(2f) >10 NT >10 >10 >10 >10 >10 41(2g) >10 NT >10 >10 >10 >10 >10 42(2h) >10 NT >10 >10 >10 >10 >10 43(2i) 6.79 >10 6.34 >10 9.87 NT 0.66 44(2j) 3.59 >10 7.59 5.3 4.7 NT 1.16 45(2k) 2.62 9.07 9.17 3.92 3.4 NT 0.48 46(2l) 3.56 >10 >10 5.98 3.63 NT 0.69 48(2q) >10 >10 8.2 >10 >10 >10 >10 49(2r) >2.00 1.34 1.7 >2.00 >2.00 1.91 1.62 50(2s) 3.54 2.67 3.64 2.17 3.44 2.65 3.82 51(2t) >10 >10 >10 3.19 4.22 3.45 >10 52(2u) 9.32 8.44 >10 >10 9.4 5.62 9.31 53(2v) >10 >10 >10 >10 >10 >10 >10 54(2w) 1.28 1.24 2.11 1.34 1.23 1.05 1.33 57(2z) 0.0005 >10 >10 >10 >10 NT >10 58(2aa) >10 >10 >10 >10 >10 NT >10
[0394] Examples Cell Viability (GI 50 uM) in Ba / F3 Cell-lines with Each Overexpression KI(M918T / V804M / G810S M918T / V804M / G810C 48(2q) >10 >10 51(2t) 1.83 3.44 52(2u) >10 >10 49(2r) >2.00 >2.00 50(2s) 2.68 3.4 53(2v) >10 >10 54(2w) 1.17 1.27
[0395] As shown in Tables 7 and 8, it was confirmed that the compound of the example according to the present invention exhibits high inhibitory activity against cell growth of various RET mutations, including RET-KIF5B and RET-KIF5B point mutations such as V804M, V804M, V804L, G810R, G810S, G810C, G810A, M918T / V804M / G810S, and M918T / V804M / G810C.
[0396] Accordingly, it was confirmed that the compound represented by Formula 1 according to the present invention not only exhibits high inhibitory activity against RET mutations but also has high growth inhibitory activity against cells in which RET mutations are expressed, and thus can be usefully used in the treatment of cancers in which RET mutations such as V804M, V804L, G810R, G810S, G810C, G810A, M918T / V804M / G810S, M918T / V804M / G810C are expressed.
[0397] From the above results, it can be seen that the pyrimidine derivative compound according to the present invention can effectively inhibit RET and RET mutations, and thus can be usefully used as a pharmaceutical composition for the prevention or treatment of cancer.
Claims
Claim 1 A compound represented by the following chemical formula 1, or a pharmaceutically acceptable salt thereof: [Chemical Formula 1] In the above chemical formula 1, X is N or CH and R 1 Silver halogen, 3-6 cycloalkyl, -NHR 1a , -OR 1b , 6-membered heterocycloalkyl, 5-6-membered heteroaryl, benzo[d][1,3]dioxolyl, CF3, nitro, or NH2, where R 1a and R 1b is independently a 3-6 cycloalkyl, substituted C 1-6 Alkyl, unsubstituted, or C 1-6 alkyl-substituted 5-6-membered heteroaryls, or C 1-6 It is an alkoxyphenyl, and the above-mentioned substituted C 1-6 The alkyl group is a 3-6-membered cycloalkyl, a 3-6-membered heterocycloalkyl, or C 1-6 The alkyl group is substituted with a 1 or 2-substituted amino; R 2 -COR 2a , -CONR 2b R 2c , a halogen, or a 5-6-membered heteroaryl, where R 2a is H, OH, or C 1-6 It is an alkyloxy, and R 2b is C 1-6 Alkyl, 3-6 cycloalkyl, C 1-6 Alkoxyphenyl, unsubstituted or C 1-6 alkyl-substituted 5-6-membered heteroaryls, or C-substituted with methylpiperazinyl 1-6 It is alkyl, and R 2c is H and or,R 2b and R 2c They form a 5-6-membered heterocycloalkyl group together with the nitrogen atoms to which they are connected; R 3 is CF3, or cyano-substituted C 1-6 It is alkyl; R 4 is C 1-6 Alkyl-substituted 5-membered heteroaryl, or C 1-6 C substituted with an alkyl-substituted 6-membered heterocycloalkyl 1-6 It is alkyl and;R 5 is H, halogen, -NHR 5a , or -OR 5b and, here R 5a and R 5b C is independently substituted with a 5-6-membered heterocycloalkyl group 1-6 Alkyl, or diC 1-6 C substituted with alkylamino 1-6 It is alkyl; however, the above R 1 and R 2 Not all of them are H. Claim 2 In paragraph 1, R 1 Chloroin, compounds, or pharmaceutically acceptable salts thereof. Claim 3 In paragraph 1, R 2 chloroin, compounds, or pharmaceutically acceptable salts thereof. Claim 4 In paragraph 1, R 2 -COR 2a , or -CONR 2b R 2c and, R 2a , R 2b and R 2c is a compound as defined in Formula 1 of Claim 1, or a pharmaceutically acceptable salt thereof. Claim 5 In paragraph 1, R 1a is cyclopropyl, substituted C 1-6 Alkyl, C 1-6 alkyl-substituted 5-membered heteroaryls, or C 1-6 It is an alkoxyphenyl, and the above-mentioned substituted C 1-6 The alkyl group is cyclopropyl, 5-6-membered heterocycloalkyl, or diC 1-6 Substituted with alkylamino, and R 1b C is substituted with a 3-6-membered heterocycloalkyl group 1-6 Alkyl, or mono-C 1-6 C substituted with alkylamino 1-6 Alkyl compounds, or pharmaceutically acceptable salts thereof. Claim 6 In paragraph 1, R 5a C is substituted with a 5-6-membered heterocycloalkyl group 1-6 Alkyl, or diC 1-6 C substituted with alkylamino 1-6 It is alkyl, and R 5b C is substituted with a 6-membered heterocycloalkyl group 1-6 Alkyl compounds, or pharmaceutically acceptable salts thereof. Claim 7 In paragraph 1, X is N or CH and R 1 -NHR chloro, cyclopropyl, -NHR 1a , -OR 1b , morpholinyl, pyridyl, thiophenyl, pyrazolyl, pyrimidinyl, oxazolyl, benzo[d][1,3]dioxolyl, CF3, nitro, or NH2, and R 1a is cyclopropyl, substituted C 1-3 Alkyl, C 1-3 Pyrazolyl substituted with alkyl, or C 1-3 It is an alkoxyphenyl, and the above-mentioned substituted C 1-3 The alkyl group is cyclopropyl, piperidinyl, pyrrolidinyl, or diC 1-3 Substituted with alkylamino, and R 1b is C substituted with morpholinyl 1-3 C substituted with alkyl or aziridinyl 1-3 Alkyl, or mono-C 1-3 C substituted with alkylamino 1-3 It is alkyl and;R 2 -COR 2a , -CONR 2b R 2c , chloro, thiophenyl, or oxazolyl, where R 2a is H, OH, or C 1-3 It is an alkyloxy, and R 2b is C 1-3 Alkyl, cyclopropyl, C 1-3 Alkoxyphenyl, unsubstituted or C 1-3 Alkyl-substituted pyrazolyl, C 1-3 C substituted with alkyl-substituted isoxazolyl, pyrimidinyl, or methylpiperazinyl 1-3 It is alkyl, and R 2c is H and or,R 2b and R 2c They form methylpiperazinyl or mopolinyl together with the nitrogen atoms to which they are connected; R 3 is CF3, or cyano-substituted C 1-3 It is alkyl; R 4 is C 1-3 Alkyl-substituted imidazolyl, methylpiperazinyl-substituted C 1-3 It is alkyl and;R 5 is H, F, -NHR 5a , or -OR 5b and, R 5a is C substituted with piperidinyl 1-3 C substituted with alkyl, pyrrolidinyl 1-3 Alkyl, or diC 1-3 C substituted with alkylamino 1-3 It is alkyl, and R 5b is C substituted with morpholinyl 1-3 Alkyl compounds, or pharmaceutically acceptable salts thereof. Claim 8 In paragraph 1, X is N or CH and R 1 chloro, cyclopropylamino, cyclopropylmethylamino, (5-methyl-1H-pyrazole-3-yl)amino, 2-morpholinoethoxy, (2-(piperidin-1-yl)ethyl)amino, 2-(isopropylamino)ethoxy, (2-(pyrrolidin-1-yl)ethyl)amino, 2-(aziridin-1-yl)ethoxy, (4-methoxyphenyl)amino, 2-(dimethylamino)ethyl)amino, . , , , , , , , cyclopropyl, CF3, nitro, or NH2, and R 2 is chloro, CHO, COOH, COOMe, , , , , , , , , , , , , , or COOEt and,R 3 is CF3, or and, R 4 Is , or and, R 5 Is , , or F, a compound, or a pharmaceutically acceptable salt thereof. Claim 9 A compound or a pharmaceutically acceptable salt thereof, any one selected from the group of compounds below: <1> 6-chloro-3-((2-methyl-5-((3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylate <2> 6-chloro-3-((5-((3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)carbamoyl)-4-fluoro-2-methylphenyl)ethinyl)imidazo[1,2-b]pyridazine-2-carboxylate <3> Ethyl 6-(cyclopropylamino)-3-((2-methyl-5-((3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylate <4> Ethyl 6-((cyclopropylmethyl)amino)-3-((2-methyl-5-((3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylate <5> Ethyl 6-((5-methyl-1H-pyrazole-3-yl)amino)-3-((2-methyl-5-((3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylate <6> Ethyl 3-((5-((3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)carbamoyl)-4-fluoro-2-methylphenyl)ethynyl)-6-(2-morpholinoethoxy)imidazo[1,2-b]pyridazine-2-carboxylate <7> ethyl 3-((5-((3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)carbamoyl)-2-methyl-4-((2-(piperidine-1-yl)ethyl)amino)phenyl)ethynyl)-6-((2-(piperidine-1-yl)ethyl)amino)imidazo[1,2-b]pyridazine-2-carboxylate <8> 3-((5-((3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)carbamoyl)-2-methyl-4-(2-(piperidine-1-yl)ethoxy)phenyl)ethynyl)-6-(2-morpholinoethoxy)imidazo[1,2-b]pyridazine-2-carboxylic acid <9> Ethyl 6-chloro-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylate <10> 6-chloro-N-isopropyl-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxamide <11> 6-chloro-N-cyclopropyl-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxamide <12> 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxamide <13> 6-chloro-N-(4-methoxyphenyl)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxamide <14> 3-((6-chloro-2-formylimidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide <15> 6-(2-(isopropylamino)ethoxy)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylic acid <16> N-isopropyl-6-(2-(isopropylamino)ethoxy)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxamide <17> 5-((6-chloroimidazo[1,2-b]pyridazine-3-yl)ethynyl)-N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-fluoro-4-methylbenzamide <18> 5-((6-chloroimidazo[1,2-b]pyridazine-3-yl)ethynyl)-N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-4-methyl-2-((2-(piperidine-1-yl)ethyl)amino)benzamide <19> 5-((6-chloroimidazo[1,2-b]pyridazine-3-yl)ethynyl)-N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-((2-(diethylamino)ethyl)amino)-4-methylbenzamide <20> N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-4-methyl-2-((2-(pyrrolidin-1-yl)ethyl)amino)-5-((6-((2-(pyrrolidin-1-yl)ethyl)amino)imidazo[1,2-b]pyridazine-3-yl)ethynyl)benzamide <21> 5-((6-(2-(aziridin-1-yl)ethoxy)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-fluoro-4-methylbenzamide <22> N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-fluoro-5-((6-(2-(isopropylamino)ethoxy)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methylbenzamide <23> N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-fluoro-4-methyl-5-((6-(2-morpholinoethoxy)imidazo[1,2-b]pyridazine-3-yl)ethynyl)benzamide <24> 3-((6-chloroimidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide <25> 3-((6-(2-(aziridin-1-yl)ethoxy)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide <26> 3-((6-(2-(isopropylamino)ethoxy)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide <27> 4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(2-morpholinoethoxy)imidazo[1,2-b]pyridazine-3-yl)ethynyl)benzamide <28> 3-((6-((4-methoxyphenyl)amino)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide <29> 4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-morpholinoimidazo[1,2-b]pyridazine-3-yl)ethynyl)benzamide <30> ethyl 6-((2-(dimethylamino)ethyl)amino)-3-((2-methyl-5-((3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxylate <31> 6-chloro-N-(1-methyl-1H-pyrazol-4-yl)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxamide <32> 3-((6-chloro-2-(4-methylpiperazine-1-carbonyl)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine)-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide <33> 6-(2-(isopropylamino)ethoxy)-N-(1-methyl-1H-pyrazole-4-yl)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl))methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-b]pyridazine-2-carboxamide <34> 3-((6-(2-(isopropylamino)ethoxy)-2-(4-methylpiperazine-1-carbonyl)imidazo[1,2-b]pyridazine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide <35> 3-((2,6-dichloroimidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)benzamide <36> N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-5-((2,6-dichloroimidazo[1,2-a]pyridine-3-yl)ethynyl)-2-fluoro-4-methylbenzamide <37> 5-((2-chloro-6-(pyridin-3-yl)imidazoo[1,2-a]pyridin-3-yl)ethynyl)-N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-fluoro-4-methylbenzamide <38> 3-((2-chloro-6-(pyridin-3-yl)imidazoo[1,2-a]pyridin-3-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)benzamide <39> 3-((2-chloro-6-(thiophene-3-yl)imidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)benzamide <40> 3-((2-chloro-6-(thiophene-2-yl)imidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)benzamide <41> 3-((2-chloro-6-(1H-pyrazole-3-yl)imidazo[1,2-a]pyridin-3-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)benzamide <42> 3-((2,6-di(thiophene-2-yl)imidazoz[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)benzamide <43> 3-((2-chloro-6-(pyrimidine-5-yl)imidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide <44> 3-((2-chloro-6-cyclopropylimidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide <45> 3-((2-chloro-6-(furan-3-yl)imidazo[1,2-a]pyridin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide <46> 3-((2-(furan-2-yl)-6-(furan-3-yl)imidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide <47> 3-((6-(benzo[d][1,3]dioxol-5-yl)-2-chloroimidazo[1,2-a]pyridine-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide <48> methyl 3-((2-methyl-5-((3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylate <49> 4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((2-(morpholine-4-carbonyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-3-yl)ethynyl)benzamide <50> N-(1-methyl-1H-pyrazol-4-yl)-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide <51> 3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-N-(5-methylisoxazole-3-yl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide <52> 3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-N-(1H-pyrazol-3-yl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide <53> 3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-N-(pyrimidine-4-yl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide <54> ethyl 3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-6-nitromidazo[1,2-a]pyridine-2-carboxylate <55> 3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-6-nitromidazo[1,2-a]pyridine-2-carboxylic acid <56> Ethyl 6-amino-3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)imidazo[1,2-a]pyridine-2-carboxylate <57> 5-((2-chloro-6-(1H-pyrazole-4-yl)imidazo[1,2-a]pyridin-3-yl)ethynyl)-N-(3-(2-cyanopropane-2-yl)-5-(4-methyl-1H-imidazole-1-yl)phenyl)-2-fluoro-4-methylbenzamide <58> 3-((2-methyl-5-((4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-N-(2-(4-methylpiperazine-1-yl)ethyl)-6-nitromidazo[1,2-a]pyridine-2-carboxamide., Claim 10 A method for preparing a compound represented by Formula 1 of claim 1, comprising the step of reacting a compound represented by Formula 2 with a compound represented by Formula 3 to prepare a compound represented by Formula 1, as shown in Reaction Scheme 1 below: [Reaction Scheme 1] In the above reaction equation, R 1 , R 2 , R 3 , R 4 , and R 5 It is as defined in Chemical Formula 1 of Article 1. Claim 11 A pharmaceutical composition for the prevention or treatment of cancer containing, as an active ingredient, a compound represented by Formula 1 of Claim 1 or Claim 9, or a pharmaceutically acceptable salt thereof. Claim 12 A pharmaceutical composition according to claim 11, wherein the compound represented by the above chemical formula 1, or a pharmaceutically acceptable salt thereof, inhibits RET (Rearranged During Transfection) and mutations thereof. Claim 13 A pharmaceutical composition according to claim 12, wherein the above-mentioned RET mutation may include RET(V804M), RET(V804L), RET(G810R), RET(G810S), RET(G810C), RET(G810A), RET-CCDC6, RET-NCOA4, RET-KIF5B, RET(V804M)-KIF5B, RET(M918T / V804M / G810S), or RET(M918T / V804M / G810C), wherein the parentheses indicate the type of mutation in the RET protein. Claim 14 In paragraph 11, the above cancers are pseudomyxoma, intrahepatic cholangiocarcinoma, hepatoblastoma, liver cancer, thyroid cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, mycosis fungoides, acute myeloid leukemia, acute lymphoblastic leukemia, basal cell carcinoma, ovarian epithelial carcinoma, ovarian germ cell carcinoma, male breast cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colorectal cancer, chronic myeloid leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, ampulla of Vater cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, rhinosinus cancer, tongue cancer, astrocytoma, small intestine cancer, meningioma, esophageal cancer, glioma, renal pelvis cancer, kidney cancer, heart cancer, duodenal cancer, malignant soft tissue cancer, malignant bone cancer, malignant lymphoma, malignant mesothelioma, A pharmaceutical composition characterized by being one or more selected from the group consisting of malignant melanoma, ocular cancer, vulvar cancer, ureteral cancer, urethral cancer, cancer of unknown primary site, gastric lymphoma, gastric cancer, gastric carcinoid tumor, gastrointestinal stromal cancer, Wilms' cancer, breast cancer, penile cancer, pharyngeal cancer, gestational trophoblastic disease, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, metastatic bone cancer, metastatic brain cancer, mediastinal cancer, rectal cancer, vaginal cancer, spinal cord cancer, acoustic neuroma, pancreatic cancer, salivary gland cancer, Kaposi's sarcoma, Paget's disease, tonsil cancer, squamous cell carcinoma, lung cancer, skin cancer, anal cancer, rhabdomyosarcoma, laryngeal cancer, pleural cancer, and thymic cancer. Claim 15 A health functional food composition for the prevention or improvement of cancer containing, as an active ingredient, a compound represented by Chemical Formula 1 of Claim 1 or Claim 9, or a pharmaceutically acceptable salt thereof.
Citation Information
Patent Citations
Acetylene derivative with anti-tumor activity
CN103420977A
Methods and compositions for treating neurodegenerative diseases
KR1020140022063A
Acetylene derivative having antineoplastic activity
WO2013170774A1
Acetylene derivative capable of resisting activity of tumor
CN103421005A
Methods and compositions for treat1ng parkinson''s disease
KR1020140022062A
